← Compound index
COMPOUND RECORD / DALARGIN

DalarginДаларгин

A synthetic opioid hexapeptide, Tyr–D-Ala–Gly–Phe–Leu–Arg, derived from the naturally occurring peptide Leu-enkephalin. Studies have examined its effects in perioperative care and tissue-injury models.

StressRecovery
Source linked

What the studies found

Comparison in people · 2025

Surgery comparison reported metabolic and complication improvements

Stress-hormone response and metabolism
Lower stress-hormone release and more favorable aerobic-metabolism measures reported with the combined protocolDalargin plus carbohydrate loading versus standard perioperative care; numerical changes not available in the abstractPerioperative assessments
Postoperative complications
Fewer complications reported; counts, types and effect uncertainty not extractedNo numerical risk reduction inferred

The combined protocol was associated with lower stress-hormone responses, more favorable aerobic-metabolism measures and fewer postoperative complications. The abstract gives no figures for these differences.

Study notes · methods, sources and limitations

Participants or model 58 surgical patients with oropharyngeal cancer; 29 combined-intervention and 29 standard-care patients

Design 58 surgical patients with oropharyngeal cancer; 29 combined-intervention and 29 standard-care patients

Study groups
29 combined-intervention versus 29 standard-care patients; 58 total

Important limitations

  • Dalargin was combined with carbohydrate loading. The abstract does not quantify outcome differences or isolate Dalargin.
  • Dalargin was combined with carbohydrate loading; the independent contribution of each is unresolved. Randomization, masking and allocation concealment were not established in the abstract. Numerical complication counts, effect sizes and uncertainty require the original outcome tables. Perioperative metabolic findings do not demonstrate improved tumor control or cancer survival.
  • A combined perioperative intervention, not isolated Dalargin efficacy or an anticancer trial. Reported differences remain qualitative until outcome tables can be checked.

Siberian Journal of Oncology. 2025;24(1):29–38 · Original clinical journal publication

Original source or citation ↗

Study results and tables ↗

Animal research · 2026

Cardiac injury marker was 27% lower in stressed rats

Cardiac injury marker CK-MB
27% lower with Dalargin than stressed controlsAnimal biomarker comparison, not a clinical event reduction24-hour stress modelNo p-value or confidence interval supplied in the abstract
Pump-function response to Dalargin
Partial reversal reported; numerical treated-versus-stress functional estimates not provided
Stress model changes, not Dalargin effects
End-systolic volume doubled and left-ventricular ejection fraction fell 27%Stress versus unstressed baseline/control; these figures must not be presented as treatment improvements

In female rats under 24-hour stress, Dalargin lowered serum CK-MB by 27% versus stressed controls. Partial pump-function recovery was reported without a numerical treated-group estimate; the model itself doubled end-systolic volume and lowered ejection fraction 27%.

Study notes · methods, sources and limitations

Participants or model Female Wistar rats exposed to 24-hour immobilization

Design Female Wistar rats under 24-hour immobilization stress; Dalargin versus stressed controls. Group sizes, precision estimates and p-values not supplied by the publisher abstract.

Reported animal protocol
0.125 mg/kg intraperitoneally, before and twice during the stress periodExperimental regimen; not clinical administration advice

Important limitations

  • An animal experiment; functional recovery was only described qualitatively and human benefit was not tested.
  • Animal stress model; this does not establish cardioprotection in people. Sample size, masking and full statistical methods require the complete paper.
  • Preclinical stress-injury model. No evidence here for human stress cardiomyopathy treatment or reduced cardiovascular events.

Bulletin of Experimental Biology and Medicine. 2026;182(8):129–133. · Indexed abstract

Original source or citation ↗

Study results and tables ↗

Animal research · 2021

2021 bone study: GHK plus Dalargin improved neutrophil measures

Study of multiple preparations

Phagocytic index: GHK plus Dalargin
71.3 ± 5.1% versus 30.8 ± 3.1% in fracture controlsUninjured control 70.7 ± 7.0%; n=8/group; M±m as printedDay 10p<0.05 versus fracture control; Table 1 marks *2
Phagocytosis activation index: GHK plus Dalargin
2.4 ± 0.3 versus 0.4 ± 0.03 in fracture controlsUninjured control 2.7 ± 0.2; GHK alone 1.2 ± 0.1; Dalargin alone 1.3 ± 0.1Day 10p<0.05 versus fracture control; pairwise superiority to single peptides not established by table symbols
Oxygen-dependent reserve: GHK alone
No significant increase versus fracture controls; remained below the uninjured referenceFigure 5 group 2 has no fracture-control significance star; no exact bar values digitizedDay 10Figure marker indicates p<0.05 versus uninjured animals

At day 10, GHK plus Dalargin had a phagocytic index of 71.3±5.1% versus 30.8±3.1% in fracture controls. GHK alone did not significantly improve oxygen-dependent neutrophil reserve. Bone-repair findings were qualitative.

More reported outcomes
Oxygen-dependent reserve: GHK plus Dalargin
Increased versus fracture controls; not marked different from the uninjured referenceFigure 5 group 5; this does not establish equivalence to healthy animalsDay 10p<0.05 versus fracture control; exact plotted values not extracted
GHK plus Thymogen: phagocytic index
75.3 ± 5.9% versus 30.8 ± 3.1% in fracture controlsThis combination also improved uptake; its oxygen-dependent reserve did not show the same restoration pattern as GHK plus DalarginDay 10p<0.05 versus fracture control; Table 1
Bone repair
More advanced callus remodeling described with GHK combinations; fracture line described as barely visibleQualitative histology/radiography, not a quantified union-time or strength endpointDay 10
Safety and clinical outcomes
No formal adverse-event series, infection-rate reduction or human treatment outcome reported
Study notes · methods, sources and limitations

Participants or model Male Wistar rats with experimental femoral fracture; Table 1 lists eight groups, n=8/group; overall cohort flow not separately specified

Design Male Wistar rats with experimental femoral fracture; Table 1 lists eight groups, n=8/group; overall cohort flow not separately specified. Eight displayed groups: uninjured saline, fractured saline, three single peptides and three pairwise combinations. Assessments at day 10; local intraosseous exposure.

Assay group sizes
Table 1 and Figure 5 report n=8/group; histology sample flow not separately established

Important limitations

  • Eight rats per assay group; local experimental delivery. GHK alone did not significantly improve oxygen-dependent reserve. Bone-repair findings are qualitative.
  • Small animal groups; randomization, blinded assessment, power calculation and complete participant flow are not described. The numerical endpoints are neutrophil assays, not fracture-union time, mechanical bone strength or clinical infection rates. Table significance symbols compare uninjured or fracture controls; they do not establish equivalence to healthy animals or a formal combination-interaction effect. Local intraosseous administration differs from the systemic 2011 patent experiment. Shared authors and related models do not establish independent replication; cohort overlap is unresolved. The peptide tested was unbound GHK, not GHK-Cu. Pairwise combinations used two peptides per group. The study had no three-peptide cocktail.
  • This is an original animal study, not a clinical review. Neutrophil uptake and oxygen-dependent reserve are surrogate assays; bone outcomes are descriptive. The claimed synergy lacks a formal interaction test. The 2021 local-delivery study and the 2011 systemic patent belong to a related research program; independent replication or shared animals cannot be established from the available reports.

Humans and their Health / Chelovek i ego zdorovye. 2021;24(4):59–67 · Original preclinical journal study; not a literature review

Original source or citation ↗

Source for the reported results ↗

Study results and tables ↗
01 / OVERVIEW

About Dalargin

Names in this research collection

Dalargine · Tyr–D-Ala–Gly–Phe–Leu–Arg

Identity / background source ↗

Research background

A Soviet synthetic opioid hexapeptide investigated in cytoprotection, stress, hypoxia, ischemia and trauma. Its enkephalin lineage is distinct from organ-derived peptide bioregulators; historical proposals and laboratory effects are not established clinical indications.

Pregnancy and offspring research

Neonatal Dalargin reportedly normalized liver growth/proliferation and nucleolar measures after prenatal hypoxia. The non-opioid analogue did not normalize all measures. Both reduced oxidative-stress indices; neither was administered to pregnant animals in this study.

Postnatal animal treatment, not maternal administration or human neonatal efficacy.

Reported findings and methods ↗ · Pregnancy research: full evidence review and archive ↗

Shustov papers, coauthors and archival leads ↗

More study findings

Completed trial · registry only · 2020

Registered Dalargin and Leitragin COVID-19 trial

The registry lists a completed 320-person Phase III trial with standard care, Dalargin, Leitragin and combination arms. No results are posted in the registry.

Study notes · methods, sources and limitations

Participants or model 320 actual enrollees reported. The four arm descriptions list 80 participants apiece.

Design Open-label randomized parallel-group study. The registry provides actual overall enrollment and describes four planned groups.

Actual enrollment
320 participants

Important limitations

  • Intervention labels and dose descriptions conflict in the registry. The arm summaries follow the detailed descriptions. The listed treatment reflects 2020 study methods.

ClinicalTrials.gov NCT04346693. · Trial registry

Original source or citation ↗

Study results and tables ↗

Animal research · 2014

Twenty-one-day loaded swimming comparison

Study of multiple preparations

Dalargin · first swim
79.7±5.4 → 218.0±6.6 sDay 0 to 21. Second and third day-21 swims: 187.3±5.4 and 181.6±6.7 s.
Control · first swim
63.8 → 71.9±3.9 sDay 0 to 21. Control rose to 91.4±3.3 s on day 28.

Cortexin and Dalargin were given to separate rat arms.

Study notes · methods, sources and limitations

Participants or model Rats in separate Cortexin, Dalargin and control arms. Per-arm n remains unconfirmed.

Design Repeated forced swimming with a 7%-body-mass load. Three swims per test session measured persistence and recovery. Tests before treatment, on days 7, 14 and 21, and one week after dosing.

Important limitations

  • Baseline swimming means differed.
  • Unequal baseline results, non-equivalent doses and repeated training exposure limit between-group interpretation.
  • The arms compare the peptides individually. They do not test a Cortexin–Dalargin combination.

Essays on Sports Pharmacology, Vol. III, Vectors of Pharmacoregulation, Chapter 5, pp. 148–151, Table 9 · Essays on Sports Pharmacology, Vol. III, Vectors of Pharmacoregulation, Chapter 5, pp. 148–151, Table 9

Original source or citation ↗

Study results and tables ↗

Comparison in people · 1998

1998 ulcer study: immune changes reported; pairing unresolved

Study of multiple preparations

T-cell immune measurements
Improvement toward healthy-reference levels reported; no numerical treatment effect or arm-specific denominator suppliedE-rosette and theophylline-sensitive/resistant assays; healthy donors are reference controls, not an untreated ulcer-treatment arm
Unchanged index and source inconsistency
The abstract says TFS-RFC did not differ from controls before or after treatmentThe same abstract uses inconsistent TPP/TPS/TFP/TFS abbreviations and also lists reduced indices; exact subset interpretation requires the original paper
Clinical healing and safety
No ulcer-closure rate, relapse rate, adverse-event count or combination-specific clinical endpoint in the abstract

The abstract reports movement of reduced T-cell rosette indices toward healthy-reference values during peptide-containing care. It does not establish which patients received each peptide or whether the pair was given together.

Study notes · methods, sources and limitations

Participants or model 120 patients with uncomplicated duodenal ulcer; 30 healthy donors used as immune-reference controls. Treatment-arm sizes and allocation are unavailable.

Design 120 patients with uncomplicated duodenal ulcer; 30 healthy donors used as immune-reference controls. Treatment-arm sizes and allocation are unavailable.

Clinical cohort
120 ulcer patients and 30 healthy donorsThese totals do not establish randomization, treatment-group sizes or simultaneous dual treatment
Dose, route and schedule
Not supplied in the abstract

Important limitations

  • 120 ulcer patients and 30 healthy-reference donors. Treatment arms, simultaneous use, doses and clinical healing outcomes are unavailable; one subset measure was unchanged.
  • Original treatment-arm table, doses, routes, concurrent care, allocation and follow-up not recovered. Historical rosette subpopulations must not be relabeled as modern flow-cytometry CD4/CD8 or regulatory T-cell measurements. Healthy donor references do not control for other ulcer treatments. The abstract does not prove simultaneous coadministration, additive benefit or synergy.
  • This is the direct human research lead, with unresolved exposure assignment. It is not a verified combination trial or a validated healing regimen. The neutral sentence and inconsistent abbreviations remain visible.

Lik Sprava. 1998;(3):56-58. PMID 9695565 · Original journal publication

Original source or citation ↗

Study results and tables ↗

Animal research · 1995

Rat ulcer comparison ranked three separate peptide preparations

Study of multiple preparations

Relative protective activity
Mucosalin > Dalargin > Thymalin, as ranked in the abstractQualitative ranking; no effect size, uncertainty or pairwise significance provided
Combination exposure
No simultaneous Thymalin plus Dalargin administration established by the abstract

The authors described protection in the order Mucosalin > Dalargin > Thymalin. The abstract gives no numerical lesion scores or combined-treatment result.

Study notes · methods, sources and limitations

Participants or model 80 male Wistar rats across an experimental duodenal-ulcer comparison; per-arm numbers unavailable.

Design 80 male Wistar rats across an experimental duodenal-ulcer comparison; per-arm numbers unavailable.

Animal program
80 male Wistar rats in totalNot 80 rats per peptide and not a human cohort

Important limitations

  • Dose, route, duration, individual arm sizes and lesion-score tables are unavailable in the abstract. Mucosalin is a separate experimental extract; its result is not transferred to either Thymalin or Dalargin. Comparative animal protection is not evidence of synergy or human ulcer healing.
  • Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.

Lik Sprava. 1995;(1-2):53-55. PMID 7483545 · Original journal publication

Original source or citation ↗

Study results and tables ↗

Animal research · 1987

Wound blood flow increased; unaffected-tissue flow was unchanged

Wound microcirculation
Increased granulation-tissue blood flow, new capillary formation and lower vascular resistance describedMicrosphere method; no numerical flow values or effect uncertainty in the abstract
Unaffected tissue
No effect on capillary blood flow reportedNeutral tissue-specific finding
Preparation boundary
The tested preparation was a collagen–Dalargin complexNo Thymalin co-treatment or general formulation equivalence established

A collagen–Dalargin preparation increased wound-granulation blood flow and capillary formation, while capillary blood flow in unaffected tissue was unchanged.

Study notes · methods, sources and limitations

Participants or model Rat skin-wound/granulation-tissue experiment; sample sizes unavailable in the indexed abstract.

Design Rat skin-wound/granulation-tissue experiment; sample sizes unavailable in the indexed abstract.

Important limitations

  • Original carrier controls, dose, route, sample sizes and numerical hemodynamic tables require full text. A local wound-flow finding is not a general increase in systemic circulation or proof of clinical healing.
  • Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.

Biull Eksp Biol Med. 1987;104(12):651-654. PMID 2446676 · Original journal publication

Original source or citation ↗

Study results and tables ↗

Animal research · 1988

Rat wounds: threefold fibroblast mitotic-index increase

Fibroblast proliferation
3-fold increase in mitotic index reportedRat wound tissue; raw indices, uncertainty and route-specific contrasts unavailable
Repair outcomes
Capillary growth, granulation/scar maturation and epithelialization described as fasterNo verified numerical days-to-closure estimate; threefold mitosis is not threefold faster healing
Safety
No adverse-event counts or long-term scarring outcomes supplied

The abstract reports a threefold fibroblast mitotic-index increase, capillary growth and faster maturation/epithelialization in rat wounds. It does not give a numerical reduction in healing days.

Study notes · methods, sources and limitations

Participants or model Rat skin wounds; group sizes and observation times absent from the abstract.

Design Rat skin wounds; group sizes and observation times absent from the abstract.

Reported routes
Intraperitoneal injection and local applicationDose, frequency and duration not supplied by the abstract

Important limitations

  • Dalargin alone, via injection or local application. The abstract does not quantify days to healing, dose or group sizes; no Thymalin synergy was tested.
  • No dose, denominator, exact observation schedule or numerical healing-time table in the abstract. Separate single-agent animal research; it does not establish Thymalin–Dalargin synergy or human wound benefits.
  • Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.

Biull Eksp Biol Med. 1988;106(10):487-490. PMID 3191245 · Original journal publication

Original source or citation ↗

Study results and tables ↗

Lab research · 1987

Dalargin inhibited stimulated human lymphocyte proliferation

Mitogen-induced proliferation
Inhibited by Dalargin at 10⁻¹²–10⁻⁷ MHuman-cell assay; no numerical inhibition percentage or donor count supplied
Naloxone contrast
Blocked the reported Dalargin-associated inhibitionAssay-specific pharmacology, not proof of a beneficial immune effect in people

Dalargin inhibited phytohemagglutinin-driven lymphocyte proliferation at 10⁻¹²–10⁻⁷ M; naloxone blocked that effect.

Study notes · methods, sources and limitations

Participants or model Cultured human peripheral-blood lymphocytes stimulated with polyclonal mitogens; donor and replicate counts unavailable.

Design Cultured human peripheral-blood lymphocytes stimulated with polyclonal mitogens; donor and replicate counts unavailable.

Experimental concentration
Dalargin 10⁻¹²–10⁻⁷ M; naloxone range 10⁻⁸–10⁻⁶ MCulture concentrations, not human doses; timing unavailable

Important limitations

  • No donor count, numerical response curve or effect uncertainty in the abstract. Opioid ligands and mitogen conditions differ; no Thymalin combination or human immune outcome was tested.
  • Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.

Farmakol Toksikol. 1987;50(3):58-59. PMID 3038604 · Original journal publication

Original source or citation ↗

Study results and tables ↗

Lab research · 1987

Dalargin’s immune effects changed with initial cell responsiveness

Lymphocyte proliferation
Increase or decrease depended on baseline responsiveness to phytohemagglutininBidirectional culture response; not a uniform immune stimulant
Leukocyte migration
Inhibition reported with Dalargin 0.1 µg/mLCulture assay; numerical migration change unavailable

Dalargin increased or decreased mitogen-driven proliferation depending on the initial cellular response, and inhibited leukocyte migration at 0.1 µg/mL.

Study notes · methods, sources and limitations

Participants or model Human-serum observational component from 55 patients, plus separate in-vitro lymphocyte and leukocyte assays. The 55 is not a Dalargin-treated cohort.

Design Human-serum observational component from 55 patients, plus separate in-vitro lymphocyte and leukocyte assays. The 55 is not a Dalargin-treated cohort.

Serum correlation component
Serum from 55 patients; endogenous leu-enkephalin inversely correlated with mitogen responsivenessObservational association, not 55 patients receiving Dalargin

Important limitations

  • In-vitro donor counts, response magnitudes and exposure duration unavailable in the abstract. Observational serum results and drug-exposure experiments are different components.
  • Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.

Zh Mikrobiol Epidemiol Immunobiol. 1987;(3):65-68. PMID 3591128 · Original journal publication

Original source or citation ↗

Study results and tables ↗

Lab research · 1988

NK-cell contacts and activity increased in a human-cell assay

NK-cell function
More effector–target contacts and active NK cells describedK-562 laboratory target assay; no clinical cancer outcome or numerical benefit estimate
Naloxone finding
At 10⁻⁶ M, naloxone itself enhanced target contacts and lytic activity in this assayDifferent response from the 1987 proliferation-blockade experiment; receptor effects are assay-dependent

Dalargin increased NK–target binding and the proportion of active NK cells in vitro. The abstract gives concentrations but no numerical cytotoxicity effect size.

Study notes · methods, sources and limitations

Participants or model Human peripheral-blood lymphocytes tested against K-562 target cells; donor and replicate counts unavailable.

Design Human peripheral-blood lymphocytes tested against K-562 target cells; donor and replicate counts unavailable.

Experimental exposure
Dalargin preincubation at 10⁻¹⁴–10⁻⁸ MDuration unavailable; the later peak-range sentence has a malformed exponent and is not reconstructed

Important limitations

  • Original response curves, donor counts and route-independent safety require full text. One activity-peak exponent is malformed in the indexed abstract; no corrected range is asserted. Natural cytotoxicity in vitro is not anticancer efficacy.
  • Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.

Biull Eksp Biol Med. 1988;105(4):442-445. PMID 3359025 · Original journal publication

Original source or citation ↗

Study results and tables ↗

Lab research · 1994

Timing-sensitive opioid effects in lymphocyte cultures

Timing-dependent culture response
Largest opioid-class stimulation described after addition at 24–48 hoursClass-level statement under suboptimal antigen conditions; not a Dalargin-specific human schedule
Ligand differences
Selective mu- and delta-ligands had effects in different directionsDAGO and DADLE findings are not assigned to Dalargin
Dalargin-specific quantitative gap
No separate numerical Dalargin effect or concentration table provided

The abstract describes an opioid-class stimulation maximum when added 24–48 hours after culture initiation under suboptimal antigen conditions. It does not isolate a quantitative Dalargin-specific maximum.

Study notes · methods, sources and limitations

Participants or model Alloantigen-stimulated mixed-lymphocyte cultures; species, sample counts and quantitative Dalargin-specific response unresolved in the abstract.

Design Alloantigen-stimulated mixed-lymphocyte cultures; species, sample counts and quantitative Dalargin-specific response unresolved in the abstract.

Important limitations

  • Concentrations, denominators, uncertainty and precise ligand-specific contrasts require the full paper. Culture timing is not a clinical administration schedule and does not establish Thymalin combination benefit.
  • Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.

Eksp Klin Farmakol. 1994;57(1):57-61. PMID 8142868 · Original journal publication

Original source or citation ↗

Study results and tables ↗

Lab research · 1994

NK-cell cytolysis increased in a separate laboratory report

NK-cell cytolysis
Increase described with Dalargin and endogenous peptidesCell-culture endpoint, not a clinical antitumor response
Numerical extraction gap
No concentration, effect magnitude, denominator or uncertainty in the abstract

Dalargin and endogenous opioid peptides enhanced NK-cell cytolytic activity in the abstract; no numerical effect size was supplied.

Study notes · methods, sources and limitations

Participants or model Natural-killer-cell culture assays; the indexed record includes mouse/animal terms, not a human treatment cohort. Sample counts unavailable.

Design Natural-killer-cell culture assays; the indexed record includes mouse/animal terms, not a human treatment cohort. Sample counts unavailable.

Important limitations

  • The concentration in the 1988 human-cell assay applies only to that experiment. No Thymalin combination, human treatment or cancer-survival benefit established.
  • Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.

Eksp Klin Farmakol. 1994;57(1):55-57. PMID 8142867 · Original journal publication

Original source or citation ↗

Study results and tables ↗

Comparison in people · 1991

Mucosal DNA-synthesis marker increased during a 20-day comparison

Mucosal DNA-synthesis marker
Significant increase in labelled epithelial nuclei described after DalarginFundal and duodenal-bulb biopsies; exact indices, p-value and group sizes unavailable20 days
Clinical endpoint gap
No numerical ulcer-closure, relapse, symptom or safety comparison in the abstract

After 20 days, Dalargin was associated with a higher index of DNA-synthesizing epithelial nuclei in fundal and duodenal-bulb mucosa than conventional care. No numerical index was supplied.

Study notes · methods, sources and limitations

Participants or model Duodenal-ulcer patients treated with Dalargin or conventional spasmolytic/antacid care; group sizes unavailable in the abstract.

Design Duodenal-ulcer patients treated with Dalargin or conventional spasmolytic/antacid care; group sizes unavailable in the abstract.

Important limitations

  • Historical active comparator; allocation, masking and other ulcer care require full text. A proliferation marker is not a demonstrated clinical healing or combination-treatment benefit.
  • Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.

Klin Med (Mosk). 1991;69(3):75-77. PMID 2067344 · Original journal publication

Original source or citation ↗

Study results and tables ↗

Animal research · 2007

Dalargin’s mucin effects differed by tissue compartment and timing

Villus mucin-production index
Reported baseline 60.56±4.01; 110.2±0.75 at day 3 with DalarginHistochemical index, source-specific units; not an 82% clinical healing benefit. Original uncertainty type not defined.
Separate untreated-ulcer reference
57.7±0.95 reported for villus mucin production without DalarginConclusion gives this reference separately; no matched-time treatment effect or confidence interval inferred
Crypt mucin response in ulcer conditions
No response to Dalargin over the first three days describedNeutral location-specific finding, despite the favorable villus narrative

The paper reports phase- and tissue-dependent mucin changes: a villus mucin-production index rose from a reported baseline 60.56±4.01 to 110.2±0.75 by day 3; early crypt and trefoil responses were mixed.

More reported outcomes
Intact-mucosa early crypt coefficient
2.19±0.07 in controls versus 1.85±0.1 after DalarginNeutral-mucin cytochemical coefficient; an early decrease, not uniform stimulationDay 1p<0.01
Trefoil-peptide signal
Early fall after Dalargin in ulcer-bearing animals, followed by return toward initial levels on days 2–3Qualitative histochemistry; no clinical consequence established
Study notes · methods, sources and limitations

Participants or model Male Wistar rats, intact mucosa and experimental duodenal-ulcer conditions; three described groups, but animal counts not reported.

Design Male Wistar rats, intact mucosa and experimental duodenal-ulcer conditions; three described groups, but animal counts not reported.

Important limitations

  • No animal group sizes, masking or complete statistical plan supplied. Histochemical indices are surrogate tissue measures, not clinical ulcer-healing percentages. The source gives both a general baseline and an untreated-ulcer reference; they are not interchangeable control time points. Intact and ulcer-bearing animals show different time courses. Dose is explicitly printed for the intact group but not repeated for the ulcer group.
  • This paper extends the mucosal-repair hypothesis while showing phase- and compartment-dependent responses. It is not a Thymalin combination experiment or a quantified clinical healing trial.

Uspekhi sovremennogo estestvoznaniia. 2007;(12, part 1):33–36. · Original animal journal publication

Original source or citation ↗

Study results and tables ↗

Animal research · 2016

Correction of Negative Effect of Antenatal Hypoxia on Liver Tissue Homeostasis in Newborn Albino Rats with Opioid Peptides

Dalargin
Reported normalization of gravimetric, proliferation and hepatocyte nucleolar measures
Non-opioid analogue: incomplete effect
Gravimetric and nucleolar parameters not normalized; proliferating-cell pool increasedRelated analogue is not Dalargin
Redox outcomes
Both preparations reduced free-radical oxidation and improved antioxidant defenses; numerical effects unavailable

Neonatal Dalargin reportedly normalized liver growth/proliferation and nucleolar measures after prenatal hypoxia. The non-opioid analogue did not normalize all measures. Both reduced oxidative-stress indices; neither was administered to pregnant animals in this study.

Study notes · methods, sources and limitations

Participants or model Seven-day-old rats after antenatal hypoxia; peptide exposure on postnatal days 2–6; n absent from abstract

Design Dalargin or a non-opiate Leu-enkephalin analogue, 100 µg/kg on postnatal days 2–6; day-7 liver growth, proliferation, nucleolar and redox assays.

Important limitations

  • Postnatal animal treatment, not maternal administration or human neonatal efficacy.
  • Postnatal animal treatment, not maternal administration or human neonatal efficacy. Abstract gives no group n, exact numerical effects, comprehensive safety series or proof of normal adult liver function. The related analogue’s exact preparation must be verified separately before assigning its results to a specific NALE formulation.

Bulletin of experimental biology and medicine. 2016;162(2):203. PMID 27909965 · Original journal publication

Original source or citation ↗

Study results and tables ↗

Animal research · 2020

Dalargin in the 2020 peptide-profile study

Findings for Dalargin within a multi-preparation animal study

Dalargin: hypoxia time
170±8 s versus displayed control 95±3 sTable 2, M±m; male rats; ten per group
Dalargin: loaded swimming
201±12 s versus displayed control 135±6 sTable 2, M±m; female rats; ten per group; 10% body-weight load

Hypoxia and swimming results came from separate animal cohorts. The original raw times and dose statements are retained below.

Study notes · methods, sources and limitations

Participants or model Outbred rats; ten per treatment group and separate control groups for each endpoint. Hypoxia: three-month-old males, 250±20 g. Loaded swimming: pretrained females, 200±20 g. A pooled analysis of separate experiments, not a verified single contemporaneous head-to-head cohort.

Design Ten rats per group; males for chamber hypoxia (time to agonal signs) and females for loaded swimming (time to exhaustion). Single rectal exposure one hour before testing; saline vehicle controls. Separately performed experiments were standardized and pooled.

Reported animal exposure
Dalargin 0.56 mg/kg rectally, once, one hour before testingExperimental route; not a human regimen

Important limitations

  • Different experiments and unequal doses limit comparisons. The 2019 book reproduces these results; it is not independent confirmation. The paper gives no pairwise p-value showing superiority for this preparation.
  • Different-sex cohorts and separate experiments contributed to the two endpoints; randomization is stated, but masking, allocation concealment and complete animal flow are not established. Doses were unequal, and the nominal experimental-preparation dose in methods conflicts with the discussion maximum. Table 2 does not resolve each complex’s actual exposure. Table 2 reports M±m; its uncertainty notation is retained without relabeling it as a verified SD. No preparation-specific pairwise p-values or confidence intervals establish PPK-V superiority over Cortexin. T-scores standardize results against experiment-specific controls. Their percentages and ratios cannot be interpreted as proportional increases in raw swim time or clinical performance. Table 1’s final bin is printed >1 kDa, while the narrative describes <1 kDa. Some fractions do not sum to 100%; blank cells are not assumed zero and values are not renormalized. The 5–10 kDa association is observational within the pooled analysis, not isolation of an active sequence or proof of brain penetration. Rectal results do not establish intranasal delivery. Matching 2019 and 2020 numerical tables are treated as one research program. No human PPK-V efficacy or long-term safety follows from these results.
  • This is a composition–activity hypothesis from pooled animal experiments. PPK-V is a distinct experimental cortex hydrolysate, not Cortexin or the brainstem PPK-B. Unequal exposures, source inconsistencies and matching earlier tables limit comparisons. No clinical superiority, formal combination synergy or intranasal PPK-V delivery has been established.

Search for the optimal mass profile of neuropeptides for the implementation of antihypoxic and activating actions. Pharmacy Formulas. 2020;2(4):72–81. · Original animal and analytical journal research

Original source or citation ↗

Study results and tables ↗

Animal research · 2014

GHK, Dalargin and Thymogen in rat fracture: 2014 neutrophil results

Study of multiple preparations

Neutrophil phagocytic index
69.17 ± 3.70% with GHK + Dalargin and 72.17 ± 5.25% with GHK + Thymogen versus 31.67 ± 2.03% with fracture plus saline.Day 10Both p<0.05 versus fracture plus saline
Phagocytic index with GHK alone
41.80 ± 2.50% with GHK, versus 31.67 ± 2.03% with fracture plus saline and 67.01 ± 4.33% without fracture.Table 1 marks p<0.05 versus both controls
Fracture radiographs
The authors describe a less visible fracture line in treated groups, particularly with combinations.Descriptive assessment

After ten days, 69.17% of neutrophils took up latex particles with GHK + Dalargin and 72.17% with GHK + Thymogen versus 31.67% with fracture plus saline.

Study notes · methods, sources and limitations

Participants or model Wistar rats (180–220 g) in a closed femoral fracture model. Table 1 lists eight groups with eight rats per group, including uninjured and fractured controls.

Design The researchers fixed a closed right femoral fracture with an intramedullary wire. After ten days they measured neutrophil uptake of latex particles, counting 100 cells per smear.

Important limitations

  • The 2021 Mal conference paper repeats treatment-group phagocytosis means and errors exactly. The two reports are treated as overlapping evidence. The separate 2021 journal paper used intraosseous delivery and reports different numbers. The paper describes radiographs qualitatively. The cellular assays do not establish fracture union, mechanical bone strength or clinical effects.

Innovations in Medicine, Kursk State Medical University conference proceedings. 2014; pp. 256–258. · Conference proceedings paper

Original source or citation ↗

Study results and tables ↗

Animal research · 2021

GHK and Dalargin after rat fracture: neutrophil reserve in the 2021 conference report

Study of multiple preparations

Stimulated NBT response in blood neutrophils
2.9× with GHK + Dalargin, 1.75× with GHK + Thymogen and 1.74× with Thymogen + Dalargin.Reported fold changes versus fracture control
Neutrophil functional reserve
1.69× with GHK + Dalargin, 1.31× with GHK + Thymogen and 1.28× with Thymogen + Dalargin.Versus fracture control. GHK + Dalargin approached the uninjured reference.Day 10
Oxygen-dependent measures with GHK alone
The authors reported no substantial effect.Figure 1 and results text

GHK plus Dalargin raised the stimulated neutrophil NBT lab signal 2.9-fold and functional reserve 1.69-fold. GHK alone showed no substantial change on these oxygen-dependent measures.

More reported outcomes
Latex uptake
The GHK + Dalargin and GHK + Thymogen phagocytic indices were 69.17 ± 3.70% and 72.17 ± 5.25%, matching the 2014 results.
Study notes · methods, sources and limitations

Participants or model The 2021 methods report 60 Wistar rats overall, with no per-arm allocation table. The overlapping 2014 publication gives eight rats per phagocytosis group. The denominators cannot be reconciled from the reports.

Design At day 10 the investigators assessed neutrophil oxidative activity using spontaneous and stimulated nitroblue tetrazolium (NBT) reduction. Functional reserve was the ratio of stimulated to spontaneous NBT. They also measured uptake of latex particles.

Important limitations

  • The published phagocytosis values repeat the 2014 report. The 60 animals stated in the 2021 methods are treated as overlapping with the earlier report. The 2021 intraosseous journal paper is a separate source with different methods and results. A normal-range laboratory result alone cannot establish equivalence to uninjured animals. These experiments do not establish a combined clinical effect or reduced infection rates.

Belikov Readings, 9th International Scientific and Practical Conference proceedings. Pyatigorsk, 2021; pp. 230–237. · Conference proceedings paper

Original source or citation ↗

Study results and tables ↗

Comparison in people · 2023

Dalargin and oxidative stress in severe combined trauma: a prospective clinical study

Mortality
8/38 (21.1%) versus 17/66 (25.8%)p=0.6412; nonsignificant
ARDS
2/38 (5.3%) versus 14/66 (21.2%)p=0.0457
Acute kidney injury
1/38 (2.6%) versus 13/66 (19.7%)p=0.0286

Among 104 patients (38 Dalargin, 66 controls), the authors reported lower oxidative-stress markers and fewer ARDS/acute kidney injury events. Mortality and infectious complications were comparable; antioxidant activity remained below normal. Hospitalization was shorter among survivors receiving Dalargin.

More reported outcomes
Overall ICU stay
12.5 [6.0–34.5] versus 15.0 [5.0–34.0] daysMedian [IQR]; narrative prints 36.5 for the first upper quartilep=0.8635; nonsignificant
ICU stay among survivors
29.0 [12.0–36.0] versus 36.5 [21.8–54.0] daysSurvivor subset; selection may bias comparisonp=0.0015
Infection and antioxidant activity
Infections comparable; antioxidant activity remained below normal
Study notes · methods, sources and limitations

Participants or model 104 severe combined-trauma patients

Design 104 trauma patients: 38 Dalargin, 66 controls; allocation safeguards unverified.

Important limitations

  • Unequal groups; randomized allocation and blinding not established in this appraisal. Biomarker changes do not prove improved survival; survivor-only length of stay requires caution.
  • Dalargin versus standard care throughout. Unequal groups and unverified assignment prevent causal inference. No survival benefit established.

Annals of Critical Care. 2023;(4):185–196 · Publication record

Original source or citation ↗

Study results and tables ↗

Randomized study in people · 2017

[THE INFLUENCE OF DEFICIT OF ENDOGENOUS NEUROPEPTIDES ON THE CLINICAL COURSE OF CORONARY HEART DISEASE].

Insulin change
−22.4% versus −6.5%Dalargin + standard care versus standard care3 monthsp<0.001 for Dalargin changes; p<0.05 for standard-care changes
TNF-α change
−55% versus −9.4%Same randomized treatment groups3 months
IL-6 change
−56.3% versus −6.1%Same groups3 months

Dalargin added to standard care was associated with larger changes in inflammatory and metabolic blood markers than standard care alone. Clinical cardiovascular events were not the reported endpoint.

More reported outcomes
Triglyceride change
−27.2% versus −17.4%Same groups3 months
HDL cholesterol change
+17.4% versus +10.3%Same groups3 months
Other Dalargin-arm changes
β-endorphin +32.6%; leptin −36.1%; cortisol −23.9%; LDL cholesterol −14%Within-arm changes; not placebo-adjusted effects3 monthsp<0.001 reported
Study notes · methods, sources and limitations

Participants or model 123 patients with coronary heart disease and metabolic syndrome, randomized 63/60; an additional 84-patient comparison group without metabolic syndrome

Design 123 coronary-heart-disease patients with metabolic syndrome randomized to standard care (63) or adjunctive Dalargin (60); 84 additional CHD patients without metabolic syndrome formed a separate comparison group.

Studied schedule
2 mg/day for 10 days; 3 courses across 3 monthsReported study regimen

Important limitations

  • Biomarker outcomes do not establish fewer cardiovascular events. Blinding and allocation concealment are not described in the abstract. Abstract only. Full methods, sample-size details and adverse-event tables were outside the review.
  • Percentages are within-group changes. The abstract does not provide the interaction test, event rates or a cardiovascular risk reduction.

Klinicheskaia meditsina · Indexed abstract

Original source or citation ↗

Study results and tables ↗

Research updates ↗

RELATED COMBINATION RESEARCH / 8 NOVEMBER 2026

Thymalin + Dalargin: what was actually studied?

The 1998 ulcer report is a combination-related lead with unresolved treatment arms. The separate 1988 wound paper reports threefold fibroblast mitotic activity in rats; it does not establish threefold faster healing or synergy with Thymalin.

Study methods, measured results and source limits ↗ · 1998 human-study results ↗

Compound class
Synthetic enkephalin analogue
Research collection
Opioid-peptide cytoprotection · editorial grouping
Institutions in linked studies
See individual study records
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

A 104-patient trauma comparison; hearing patent case material kept separate; historical 120-patient ulcer immune report, with combination treatment arms unresolved

Study methods

Receptor assays, animal dissertations, human comparison and patents

Independent replication

Independent clinical replication not established by this collection

Source access

Indexed abstracts, publisher text, patent tables and dissertation transcriptions

Safety evidence

Delivery and clinical context matter; long-term and combination safety remain unresolved

Open a topic for the evidence assessment.

More findings, background and history
RELATED PEPTIDE RESEARCH / UPDATED OCTOBER 2026

Connections in the research

The related map now separates NALE, Sedatin and marrow-peptide research. NALE’s 2026 NOP-blockade experiment qualifies earlier mechanism proposals; its cell findings are not Dalargin clinical evidence.

View the peptide family map and sources ↗

DALARGIN / OPIOID PEPTIDES & CYTOPROTECTION

From enkephalin design to tissue-injury research

Dalargin connects endogenous opioid-peptide biology with the experimental question of tissue resistance to stress. Its D-Ala substitution and terminal arginine distinguish it from natural Leu-enkephalin. The 1999 receptor study shows why sequence, assay and formulation must remain attached to mechanistic claims. It is not interchangeable with Semax, Selank or tissue-derived bioregulators.

The Titov–Vinogradov–Bespalova citation from 1985 explicitly frames Dalargin as cytoprotective. Gastrointestinal, cardiovascular and stress research became different branches of that idea. A coherent historical rationale does not establish effectiveness across all those settings.

Mine-blast hearing injury: an unusual human report

RU2323019C1 describes combined Dalargin and electropuncture in blast-related hearing injury. It is patent case material, not a modern randomized trial. Its proposed hypoxia and microcirculation rationale is a hypothesis; the contribution of Dalargin cannot be isolated. The research record preserves the reported outcomes and the patent’s internal numerical inconsistency.

Animal survival under severe hypoxia

Kalinin’s 2000 dissertation investigates rats in a pressure chamber, comparing ordinary administration with experimental erythrocyte-carrier delivery. The reported persistence at later testing times is a question for replication, not evidence that the peptide remains in circulation for days or that a person can safely tolerate extreme altitude. Survival tables, the early time notation and original scans need reconciliation.

Stress, resuscitation and clinical trauma

Frantsuzova’s animal dissertation compares Dalargin, Picamilon and Mildronate. These are separate approaches, not an established three-agent combination. Razgonov’s dissertation abstract documents a different Dalargin–Mildronate resuscitation research program; claims of synergy need original interaction analyses.

The 2023 prospective trauma comparison is a more recent human source. Its biochemical and organ-dysfunction findings must be read alongside comparable mortality and infections, unequal groups and unresolved allocation. It does not justify an improvement-in-survival claim.

Historical combinations and delivery are separate questions

Archived proposals include Dalargin with ketorolac during prolonged evacuation, multicomponent hemorrhagic-shock care, and Bemitil, Dalargin and acupuncture for chronic hearing loss. None establishes a general-purpose stack. Topical burn formulations and erythrocyte carriers must also be distinguished from ordinary systemic Dalargin.

Bibliography and remaining research gaps

1985

Dalargin — a peptide preparation with cytoprotective action

A later paper cites the 1985 publication. The original text is unavailable here.

Source and access status ↗
1991

Synthetic peptide bioregulators in adaptation to extreme exposures

A later paper cites this dissertation. Its original results are unavailable here.

Source and access status ↗
2007

Dalargin with ketorolac during prolonged medical evacuation — RU2306146C1

Patent reproduction describes field-trauma cases and combined analgesia. Historical proposal, not independently validated treatment or an isolated Dalargin effect.

Source and access status ↗
2005

Early hemorrhagic-shock therapy — RU2258529C1

Multicomponent proposal uses Dalargin or Mildronate and makes the choice conditional on blood pressure. Not evidence for a general shock-prevention stack.

Source and access status ↗
2019

Topical hexapeptide for wound and burn injuries — RU2687485C1

Formulation-specific wound/burn research lead; not evidence that systemic Dalargin has the same effects.

Source and access status ↗
2023

Dalargin severe-trauma study — publisher PDF

Same publication as dalargin-trauma-2023, not an additional trial.

Source and access status ↗
1999

Razgonov — digital dissertation abstract

Same document as dalargin-resuscitation-1999; original tables remain a recovery priority.

Source and access status ↗

Further acquisition priorities include the Slepushkin–Zoloev–Vinogradov–Titov neuropeptide monograph (1988), Zakharova’s immobilization-stress dissertation (1988), early Zakusov–Yasnetsov opioid/hypoxia experiments, and the original military-medical anti-ischemia paper. Bibliographic details and original texts need verification before study-level findings can be entered.

Burns/DSIP comparisons, radiation/Actovegin comparisons, hypothermia and gastrointestinal clinical reports remain additional retrieval leads. Mentioning these branches does not establish positive results. Blood-pressure effects and delivery-specific safety require dedicated appraisal; peripheral action is not a safety guarantee.

Educational information only, not medical advice. Seek qualified healthcare help for any condition. Historical trauma and hypoxia experiments are not self-treatment or exposure-protection instructions.

What remains unclear

Group assignment, comparators, planned outcomes, effect estimates, adverse events and possible participant overlap are key limits to interpreting the studies.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗
PATENT RESEARCH / COLLECTION UPDATED 7 NOVEMBER 2026

Patents and claimed inventions

These 5 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.

2024 · RU2821826C1 · Dalargin: menopausal symptoms and six-month follow-upUse · 15/15 (100%) with Dalargin versus 5/8 (62.5%) with placebo

Reported findings

The inventor reports symptom improvement after Dalargin with persistence at six months. Pineamin and IPH GAA are background references, not treatments in this comparison.

Reported clinical improvement
15/15 (100%) with Dalargin versus 5/8 (62.5%) with placeboAfter the 30-day courseBroad symptom-based outcome; no prespecified responder threshold reported
Six-month follow-up
All 15 Dalargin recipients reportedly retained improvement; all 8 placebo recipients returned to baseline6 monthsFollow-up completeness and independent assessment not established
All reported results, comparisons and limitations →

Use. This 2024 patent reports a 23-woman comparison of Dalargin versus saline placebo. Pineamin is mentioned only as background, not as a tested combination.

The small unequal groups, undefined response criteria and unverified allocation and masking prevent an established treatment effect.

Publication
RU2821826C1 ↗ · 2024-06-26
Earliest priority / filing
Not established / 2024-04-13
Original applicant / assignee
Борис Юльевич Чебураков
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
Grouping identifier unavailable · family publications are related filings, not independent studies.
Original title, inventors and related publications

Method of treating climacteric syndrome in women

Inventors: Борис Юльевич Чебураков.

RU2821826C1

Original patent PDF ↗

Read source review →

2021 · EP3556377B1 · Dalargin: nasal respiratory-infection use and formulationFormulation · Reduced stimulated IL-1, IL-6 and TNF-α production reported

Findings described in words

The patent reports reduced stimulated inflammatory-cytokine production and altered innate-cell activity.

Donor-cell cytokines
Reduced stimulated IL-1, IL-6 and TNF-α production reportedIn-vitro experiment using cells from 20 donors; exact figure percentages not transcribed
Animal innate-cell findings
Increased phagocytic activity described; no detected difference between the tested routesA laboratory result, not demonstrated clinical infection recovery
All reported results, comparisons and limitations →

Formulation. The patent concerns nasal Dalargin compositions and proposed respiratory-infection applications.

A granted formulation or use claim does not establish clinical antiviral benefit.

Publication
EP3556377B1 ↗ · 2021-09-08
Earliest priority / filing
2018-04-18 / 2019-04-10
Original applicant / assignee
PVP Labs Pte Ltd
Indexed status
Active · checked 2026-11-06
Patent family
64328036 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Dalargin for use in the treatment of acute respiratory viral infections

Inventors: Evgeny Alexandrovich Chertorizhsky; Mikhail Vladimirovich Ovchinnikov; Aleksey Viktorovich Kleimenov.

EP3556377B1 · US11365216B2 · JP6952379B2 · KR20200132931A · CN112020367B · CA3093492C · EA037430B1 · ES2901193T3 · HRP20211906T1 · HUE056471T2 · MY206814A · PH12020551709A1 · PL3556377T3 · PT3556377T · RS62632B1 · RU2672888C1 · SG11202009591PA · WO2019202380A1 · ZA202006656B

Original patent PDF ↗

Read source review →

2008 · RU2323019C1 · Dalargin and electropuncture for acute hearing injury after mine blasts — RU2323019C1Use · 22.3% complete restoration, 34.7% improvement, 43% unchanged

Reported findings

Hearing improved in some patients, while 43% had no reported treatment effect.

Hearing outcome
22.3% complete restoration, 34.7% improvement, 43% unchangedAfter the treatment courseReported proportions; no modern randomized comparison established
Hearing thresholds
Average reductions reported in the 15–30 dB rangeWithin-cohort change across speech/high frequencies
All reported results, comparisons and limitations →

Use. A Dalargin method relating to blast-associated hearing injury; disease-specific patent claims do not establish routine clinical benefit.

A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.

Publication
RU2323019C1 ↗ · 2008-04-27
Earliest priority / filing
2006-11-23 / 2006-11-23
Original applicant / assignee
Государственное образовательное учреждение высшего профессионального образования "Северо-Осетинская государственная медицинская академия" Федерального агентства по здравоохранению и социальному развитию
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
39453032 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Method for treating patients for posttraumatic sensorineural deafness in acute stage caused by mine explosion injury

Inventors: Эльвира Татаркановна Гаппоева (RU); Эльвира Татаркановна Гаппоева.

RU2323019C1

Original patent PDF ↗

Read source review →

2011 · RU2429002C1 · GHK plus Dalargin: 2011 bone-repair patentUse · Fracture line described as barely visible with the combination; still visible but less pronounced with either peptide alone

Findings described in words

The authors describe more advanced early bone repair with GHK plus Dalargin than with saline or either peptide alone. The evidence is qualitative radiography and histology.

Combined treatment: radiographic appearance
Fracture line described as barely visible with the combination; still visible but less pronounced with either peptide aloneDay 10Versus saline and single-peptide groups; no numerical radiographic score or uncertainty reported
Combined treatment: histological appearance
New bone formation and remodeling toward compact bone were described as more advanced in the combination groupDay 10Descriptive morphology; no quantitative histomorphometry or factorial interaction test
All reported results, comparisons and limitations →

Related 2021 journal paper: neutrophil results → — a local-delivery rat study; its numerical results are not measurements from this patent.

Use. The claim combines unbound Gly-His-Lys with Dalargin for reparative osteogenesis; rat radiographs and histology support the disclosed rationale.

The fracture experiment tested the combination in rats. No measured shortening of healing time or biomechanical strength was reported.

Publication
RU2429002C1 ↗ · 2011-09-20
Earliest priority / filing
2010-09-13 / 2010-09-13
Original applicant / assignee
Kursk State Medical University
Indexed status
IP Right Cessation — indexed historical event; official status unverified · checked 2026-11-07
Patent family
44758621 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Method of stimulating reparative osteogenesis

Inventors: Виктор Юрьевич Чердаков; Михаил Юрьевич Смахтин; Григорий Михайлович Дубровин; Игорь Иванович Бобынцев; Виктор Тарасович Дудка; Максим Евгеньевич Долгинцев; Алексей Анатольевич Крюков; Вадим Теймуразович Корошвили; Ирина Михайловна Соболева; Евгений Николаевич Кононец; Андрей Евгеньевич Белых; Ольга Игоревна Иванова.

RU2429002C1 · RU2589264C2 · RU2589265C2 · RU2593817C2 · RU2676659C1 · WO2021211006A1 · US5367053A · RU2193868C2 · RU2195311C2 · WO2004106491A2 · RU2295969C1

Original patent PDF ↗

Read source review →

1991 · SU1674849A1 · Immune-profile-directed peptide selection with psoriasis photochemotherapyUse · Dalargin case B cells 10%→20%; Thymalin case 32%→13%; T-activin case 28.6%→14%

Reported findings

The patent chose alternative peptides for opposing lymphocyte profiles. Case immune measures changed during combined care; no simultaneous Thymalin–Dalargin regimen was established.

Alternative-treatment examples
Dalargin case B cells 10%→20%; Thymalin case 32%→13%; T-activin case 28.6%→14%One selected patient per peptide, with photochemotherapy; changes are not comparative treatment effects
Dalargin case: immune measures
T-suppressor index 9%→25%; T-helper index 71%→55%Example 2; B cells 10%→20%; historical subset methods are not modern Treg measurements
All reported results, comparisons and limitations →

Use. Selects Dalargin, Thymalin or T-activin as alternatives according to historical lymphocyte profiles, alongside photochemotherapy. Not a claim to simultaneous Thymalin–Dalargin administration.

Selected case reports with photochemotherapy and historical immune assays; no controlled pair trial or isolated peptide effect. Russian dose/frequency statements are distinguished from mistranslated English text.

Publication
SU1674849A1 ↗ · 1991-09-07
Earliest priority / filing
1989-03-20 / 1989-03-20
Original applicant / assignee
Irkutsk State Medical Institute
Indexed status
Current legal status not established from this indexed record; official register not reviewed · checked 2026-11-08
Patent family
21434935 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Способ лечения псориаза

Inventors: I. O. Malova; R. G. Skvortsova; N. P. Kuznetsova.

SU1674849A1

Original patent PDF ↗

Read source review →

Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →

03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Completed trial · registry only · 2020

Registered Dalargin and Leitragin COVID-19 trial

The registry lists a completed 320-person Phase III trial with standard care, Dalargin, Leitragin and combination arms. No results are posted in the registry.

Study notes and original source
2020Trial protocol / registrationFull text available

Registered Dalargin and Leitragin COVID-19 trial

· Trial registry

Burnasyan Federal Medical Biophysical Center · ClinicalTrials.gov NCT04346693.

The registry lists a completed 320-person Phase III trial with standard care, Dalargin, Leitragin and combination arms. No results are posted in the registry.

Results and tables

Reported findings and study design

The patent gives no measured outcomes

Open-label randomized parallel-group study. The registry provides actual overall enrollment and describes four planned groups.

Dose, route and schedule

All four arms received the study’s background care. The add-on arms specify Dalargin 1 mg intramuscularly daily for 10 days, Leitragin 10 mg by inhalation daily until pulmonary complications resolved, or both.

Protocol source ↗ · ClinicalTrials.gov record and sponsor-submitted enrollment and intervention fields.

Results · ClinicalTrials.gov record and sponsor-submitted enrollment and intervention fields.
MeasureResultComparison, timing and statistics
Actual enrollment320 participants
Arm descriptions as specified by the sponsor
Arm descriptions as specified by the sponsor
ArmListed group sizeStudy intervention alongside background care
Comparison80Background care only
Dalargin801 mg IM daily for 10 days
Leitragin8010 mg inhaled daily until pulmonary complications resolved
Combination80Dalargin plus Leitragin on the same schedules

Arm sizes in the protocol descriptions. Arm-level enrollment and outcomes are unavailable.

Source for these results ↗ · Reviewed 2026-11-15

Population / setting
320 actual enrollees reported. The four arm descriptions list 80 participants apiece.
Source reviewed
ClinicalTrials.gov record and sponsor-submitted enrollment and intervention fields.
Study limitations
  • Intervention labels and dose descriptions conflict in the registry. The arm summaries follow the detailed descriptions. The listed treatment reflects 2020 study methods.

Reviewed 2026-11-15.

Read the source ↗

Animal research · 2014

Cortexin and Dalargin during a 21-day rat swimming series

Cortexin and Dalargin were given to separate rat arms.

Study notes and original source
2014Animal / experimentalRussian-language source

Cortexin and Dalargin during a 21-day rat swimming series

· Essays on Sports Pharmacology, Vol. III, Vectors of Pharmacoregulation, Chapter 5, pp. 148–151, Table 9

Format: Original publication and selected methods and results checked · Reviewed: Reported methods, results and evidence limitations

N. N. Karkishchenko, V. V. Uyba, V. N. Karkishchenko, E. B. Shustov, K. V. Kotenko, S. L. Lyublinskiy · Essays on Sports Pharmacology, Vol. III, Vectors of Pharmacoregulation, Chapter 5, pp. 148–151, Table 9

First-swim means reached 227.25 s with Cortexin and 218.0 s with Dalargin on day 21, versus 71.9 s in controls. Starting means already differed.

Results and tables

Reported findings and study design

First-swim means reached 227.25 s with Cortexin and 218.0 s with Dalargin on day 21, versus 71.9 s in controls. Starting means already differed.

Repeated forced swimming with a 7%-body-mass load. Three swims per test session measured persistence and recovery. Tests before treatment, on days 7, 14 and 21, and one week after dosing.

Population or model Rats in separate Cortexin, Dalargin and control arms. Per-arm n remains unconfirmed.

Dose, route and schedule

Daily rectal Cortexin 5 mg/kg or Dalargin 0.56 mg/kg for 21 days, in separate arms.

Protocol source ↗ · Original publication and selected methods and results checked

Results · Original publication and selected methods and results checked
MeasureResultComparison, timing and statistics
Cortexin · first swim84.3±3.9 → 227.25±4.5 sDay 0 to 21. Second and third day-21 swims: 159.0±4.28 and 204.6±10.9 s.
Dalargin · first swim79.7±5.4 → 218.0±6.6 sDay 0 to 21. Second and third day-21 swims: 187.3±5.4 and 181.6±6.7 s.
Control · first swim63.8 → 71.9±3.9 sDay 0 to 21. Control rose to 91.4±3.3 s on day 28.
Cortexin · recovery indexTransient deterioration at day 14Recovery and first-swim duration are separate outcomes.

The arms compare the peptides individually. They do not test a Cortexin–Dalargin combination.

Source for these results ↗ · Reviewed 2026-11-09

Population / setting
Rats in separate Cortexin, Dalargin and control arms. Per-arm n remains unconfirmed.
Source reviewed
Original publication and selected methods and results checked
Study limitations
  • Unequal baseline results, non-equivalent doses and repeated training exposure limit between-group interpretation.

Reviewed 2026-11-09.

Read the source ↗

Comparison in people · 1998

The lymphocyte subpopulation in patients with duodenal ulcer and the immunocorrective activity of thymalin and dalargin

The abstract reports movement of reduced T-cell rosette indices toward healthy-reference values during peptide-containing care. It does not establish which patients received each peptide or whether the pair was given together.

Study notes and original source
1998Human comparative studyEnglish abstract

The lymphocyte subpopulation in patients with duodenal ulcer and the immunocorrective activity of thymalin and dalargin

Thymalin and Dalargin mentioned within complex therapy; simultaneous administration and the treatment arms are unresolved. · Original journal publication

Format: Original indexed abstract · Reviewed: Indexed abstract and citation checked; full original outcome tables not recovered

Lukash NV, Polishchuk TF, Ludan VV · Lik Sprava. 1998;(3):56-58. PMID 9695565

The abstract reports movement of reduced T-cell rosette indices toward healthy-reference values during peptide-containing care. It does not establish which patients received each peptide or whether the pair was given together.

Results and tables

Reported findings and study design

Findings described in words

The abstract reports movement of reduced T-cell rosette indices toward healthy-reference values during peptide-containing care. It does not establish which patients received each peptide or whether the pair was given together.

120 patients with uncomplicated duodenal ulcer; 30 healthy donors used as immune-reference controls. Treatment-arm sizes and allocation are unavailable.

Protocol information

Dose, route and treatment schedule are not sufficiently described in the abstract.

Protocol source ↗ · Original indexed abstract; protocol unavailable

Results · Original indexed abstract; full outcome tables unavailable
MeasureResultComparison, timing and statistics
T-cell immune measurementsImprovement toward healthy-reference levels reported; no numerical treatment effect or arm-specific denominator suppliedE-rosette and theophylline-sensitive/resistant assays; healthy donors are reference controls, not an untreated ulcer-treatment arm
Unchanged index and source inconsistencyThe abstract says TFS-RFC did not differ from controls before or after treatmentThe same abstract uses inconsistent TPP/TPS/TFP/TFS abbreviations and also lists reduced indices; exact subset interpretation requires the original paper
Clinical cohort120 ulcer patients and 30 healthy donorsThese totals do not establish randomization, treatment-group sizes or simultaneous dual treatment
Clinical healing and safetyNo ulcer-closure rate, relapse rate, adverse-event count or combination-specific clinical endpoint in the abstract
Dose, route and scheduleNot supplied in the abstract

This is the direct human research lead, with unresolved exposure assignment. It is not a verified combination trial or a validated healing regimen. The neutral sentence and inconsistent abbreviations remain visible.

Source for these results ↗ · Reviewed 2026-11-08

Population / setting
120 patients with uncomplicated duodenal ulcer; 30 healthy donors used as immune-reference controls. Treatment-arm sizes and allocation are unavailable.
Source reviewed
Original PubMed / Europe PMC indexed abstract checked. Missing group sizes, doses, raw outcomes and uncertainty are not reconstructed.
Study limitations
  • Original treatment-arm table, doses, routes, concurrent care, allocation and follow-up not recovered.
  • Historical rosette subpopulations must not be relabeled as modern flow-cytometry CD4/CD8 or regulatory T-cell measurements.
  • Healthy donor references do not control for other ulcer treatments. The abstract does not prove simultaneous coadministration, additive benefit or synergy.

Reviewed 2026-11-08.

Read the source ↗

Animal research · 1995

The effect of thymalin, dalargin and "Mucosalin" on the course of an experimental duodenal ulcer

The authors described protection in the order Mucosalin > Dalargin > Thymalin. The abstract gives no numerical lesion scores or combined-treatment result.

Study notes and original source
1995Animal / experimentalEnglish abstract

The effect of thymalin, dalargin and "Mucosalin" on the course of an experimental duodenal ulcer

Thymalin, Dalargin and experimental Mucosalin, a pig-gastric-mucosal extract; compared preparations, not a verified simultaneous pair. · Original journal publication

Format: Original indexed abstract · Reviewed: Indexed abstract and citation checked; full original outcome tables not recovered

Lukash NV, Polishchuk TF · Lik Sprava. 1995;(1-2):53-55. PMID 7483545

The authors described protection in the order Mucosalin > Dalargin > Thymalin. The abstract gives no numerical lesion scores or combined-treatment result.

Results and tables

Reported findings and study design

Findings described in words

The authors described protection in the order Mucosalin > Dalargin > Thymalin. The abstract gives no numerical lesion scores or combined-treatment result.

80 male Wistar rats across an experimental duodenal-ulcer comparison; per-arm numbers unavailable.

Protocol information

Dose, route and treatment schedule are not sufficiently described in the abstract.

Protocol source ↗ · Original indexed abstract; protocol unavailable

Results · Original indexed abstract; full outcome tables unavailable
MeasureResultComparison, timing and statistics
Relative protective activityMucosalin > Dalargin > Thymalin, as ranked in the abstractQualitative ranking; no effect size, uncertainty or pairwise significance provided
Animal program80 male Wistar rats in totalNot 80 rats per peptide and not a human cohort
Combination exposureNo simultaneous Thymalin plus Dalargin administration established by the abstract

Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.

Source for these results ↗ · Reviewed 2026-11-08

Population / setting
80 male Wistar rats across an experimental duodenal-ulcer comparison; per-arm numbers unavailable.
Source reviewed
Original PubMed / Europe PMC indexed abstract checked. Missing group sizes, doses, raw outcomes and uncertainty are not reconstructed.
Study limitations
  • Dose, route, duration, individual arm sizes and lesion-score tables are unavailable in the abstract.
  • Mucosalin is a separate experimental extract; its result is not transferred to either Thymalin or Dalargin.
  • Comparative animal protection is not evidence of synergy or human ulcer healing.

Reviewed 2026-11-08.

Read the source ↗

Animal research · 1987

Blood flow in skin wound tissue and systemic hemodynamics as affected by a collagen-dalargin complex

A collagen–Dalargin preparation increased wound-granulation blood flow and capillary formation, while capillary blood flow in unaffected tissue was unchanged.

Study notes and original source
1987Animal / experimentalEnglish abstract

Blood flow in skin wound tissue and systemic hemodynamics as affected by a collagen-dalargin complex

Collagen–Dalargin complex; not assumed equivalent to free Dalargin, every local formulation or a Thymalin combination. · Original journal publication

Format: Original indexed abstract · Reviewed: Indexed abstract and citation checked; full original outcome tables not recovered

Medvedev OS, Khulup GIa, Spevak SE, Istranov LP, Titov MI · Biull Eksp Biol Med. 1987;104(12):651-654. PMID 2446676

A collagen–Dalargin preparation increased wound-granulation blood flow and capillary formation, while capillary blood flow in unaffected tissue was unchanged.

Results and tables

Reported findings and study design

Findings described in words

A collagen–Dalargin preparation increased wound-granulation blood flow and capillary formation, while capillary blood flow in unaffected tissue was unchanged.

Rat skin-wound/granulation-tissue experiment; sample sizes unavailable in the indexed abstract.

Population or model Rat skin-wound/granulation-tissue experiment; sample sizes unavailable in the indexed abstract.

Protocol information

Dose, route and treatment schedule are not sufficiently described in the abstract.

Protocol source ↗ · Original indexed abstract; protocol unavailable

Results · Original indexed abstract; full outcome tables unavailable
MeasureResultComparison, timing and statistics
Wound microcirculationIncreased granulation-tissue blood flow, new capillary formation and lower vascular resistance describedMicrosphere method; no numerical flow values or effect uncertainty in the abstract
Unaffected tissueNo effect on capillary blood flow reportedNeutral tissue-specific finding
Preparation boundaryThe tested preparation was a collagen–Dalargin complexNo Thymalin co-treatment or general formulation equivalence established

Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.

Source for these results ↗ · Reviewed 2026-11-08

Population / setting
Rat skin-wound/granulation-tissue experiment; sample sizes unavailable in the indexed abstract.
Source reviewed
Original PubMed / Europe PMC indexed abstract checked. Missing group sizes, doses, raw outcomes and uncertainty are not reconstructed.
Study limitations
  • Original carrier controls, dose, route, sample sizes and numerical hemodynamic tables require full text.
  • A local wound-flow finding is not a general increase in systemic circulation or proof of clinical healing.

Reviewed 2026-11-08.

Read the source ↗

Animal research · 1988

Effects of opioid peptide dalargin on reparative processes in wound healing

The abstract reports a threefold fibroblast mitotic-index increase, capillary growth and faster maturation/epithelialization in rat wounds. It does not give a numerical reduction in healing days.

Fibroblast proliferation · 3-fold increase in mitotic index reported · Rat wound tissue; raw indices, uncertainty and route-specific contrasts unavailable

Study notes and original source
1988Animal / experimentalEnglish abstract

Effects of opioid peptide dalargin on reparative processes in wound healing

Dalargin by intraperitoneal injection and local application; route-specific effect magnitudes not separated in the abstract. · Original journal publication

Format: Original indexed abstract · Reviewed: Indexed abstract and citation checked; full original outcome tables not recovered

Shekhter AB, Solov'eva AI, Spevak SE, Titov MI · Biull Eksp Biol Med. 1988;106(10):487-490. PMID 3191245

The abstract reports a threefold fibroblast mitotic-index increase, capillary growth and faster maturation/epithelialization in rat wounds. It does not give a numerical reduction in healing days.

Results and tables

Reported findings and study design

Reported findings

The abstract reports a threefold fibroblast mitotic-index increase, capillary growth and faster maturation/epithelialization in rat wounds. It does not give a numerical reduction in healing days.

Rat skin wounds; group sizes and observation times absent from the abstract.

Population or model Rat skin wounds; group sizes and observation times absent from the abstract.

Dose, route and schedule

Intraperitoneal injection and local Dalargin application; dose, frequency and observation duration unavailable in the abstract.

Protocol source ↗ · Original indexed abstract; historical research methods

Results · Original indexed abstract; full outcome tables unavailable
MeasureResultComparison, timing and statistics
Fibroblast proliferation3-fold increase in mitotic index reportedRat wound tissue; raw indices, uncertainty and route-specific contrasts unavailable
Repair outcomesCapillary growth, granulation/scar maturation and epithelialization described as fasterNo verified numerical days-to-closure estimate; threefold mitosis is not threefold faster healing
Reported routesIntraperitoneal injection and local applicationDose, frequency and duration not supplied by the abstract
SafetyNo adverse-event counts or long-term scarring outcomes supplied

Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.

Source for these results ↗ · Reviewed 2026-11-08

Population / setting
Rat skin wounds; group sizes and observation times absent from the abstract.
Source reviewed
Original PubMed / Europe PMC indexed abstract checked. Missing group sizes, doses, raw outcomes and uncertainty are not reconstructed.
Study limitations
  • No dose, denominator, exact observation schedule or numerical healing-time table in the abstract.
  • Separate single-agent animal research; it does not establish Thymalin–Dalargin synergy or human wound benefits.

Reviewed 2026-11-08.

Read the source ↗

Lab research · 1987

Importance of opiate receptor ligands in regulating lymphocyte proliferative activity

Dalargin inhibited phytohemagglutinin-driven lymphocyte proliferation at 10⁻¹²–10⁻⁷ M; naloxone blocked that effect.

Study notes and original source
1987In vitroEnglish abstract

Importance of opiate receptor ligands in regulating lymphocyte proliferative activity

Dalargin and other opioid ligands tested in separate culture conditions. · Original journal publication

Format: Original indexed abstract · Reviewed: Indexed abstract and citation checked; full original outcome tables not recovered

Zozulia AA, Voronkova TL, Patsakova E, Ivanushkin AM · Farmakol Toksikol. 1987;50(3):58-59. PMID 3038604

Dalargin inhibited phytohemagglutinin-driven lymphocyte proliferation at 10⁻¹²–10⁻⁷ M; naloxone blocked that effect.

Results and tables

Reported findings and study design

Findings described in words

Dalargin inhibited phytohemagglutinin-driven lymphocyte proliferation at 10⁻¹²–10⁻⁷ M; naloxone blocked that effect.

Cultured human peripheral-blood lymphocytes stimulated with polyclonal mitogens; donor and replicate counts unavailable.

Population or model Cultured human peripheral-blood lymphocytes stimulated with polyclonal mitogens; donor and replicate counts unavailable.

Dose, route and schedule

Dalargin 10⁻¹²–10⁻⁷ M in stimulated human lymphocyte cultures; the abstract lists naloxone 10⁻⁸–10⁻⁶ M. Exposure duration unavailable.

Protocol source ↗ · Original indexed abstract; historical research methods

Results · Original indexed abstract; full outcome tables unavailable
MeasureResultComparison, timing and statistics
Mitogen-induced proliferationInhibited by Dalargin at 10⁻¹²–10⁻⁷ MHuman-cell assay; no numerical inhibition percentage or donor count supplied
Naloxone contrastBlocked the reported Dalargin-associated inhibitionAssay-specific pharmacology, not proof of a beneficial immune effect in people
Experimental concentrationDalargin 10⁻¹²–10⁻⁷ M; naloxone range 10⁻⁸–10⁻⁶ MCulture concentrations, not human doses; timing unavailable

Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.

Source for these results ↗ · Reviewed 2026-11-08

Population / setting
Cultured human peripheral-blood lymphocytes stimulated with polyclonal mitogens; donor and replicate counts unavailable.
Source reviewed
Original PubMed / Europe PMC indexed abstract checked. Missing group sizes, doses, raw outcomes and uncertainty are not reconstructed.
Study limitations
  • No donor count, numerical response curve or effect uncertainty in the abstract.
  • Opioid ligands and mitogen conditions differ; no Thymalin combination or human immune outcome was tested.

Reviewed 2026-11-08.

Read the source ↗

Lab research · 1987

Immunomodulating action of neuropeptides in in vitro systems

Dalargin increased or decreased mitogen-driven proliferation depending on the initial cellular response, and inhibited leukocyte migration at 0.1 µg/mL.

Study notes and original source
1987In vitroEnglish abstract

Immunomodulating action of neuropeptides in in vitro systems

Dalargin and leu-enkephalin investigated as separate ligands. · Original journal publication

Format: Original indexed abstract · Reviewed: Indexed abstract and citation checked; full original outcome tables not recovered

Karpov RS, Beĭko VA, Vasil'chenko EM · Zh Mikrobiol Epidemiol Immunobiol. 1987;(3):65-68. PMID 3591128

Dalargin increased or decreased mitogen-driven proliferation depending on the initial cellular response, and inhibited leukocyte migration at 0.1 µg/mL.

Results and tables

Reported findings and study design

Findings described in words

Dalargin increased or decreased mitogen-driven proliferation depending on the initial cellular response, and inhibited leukocyte migration at 0.1 µg/mL.

Human-serum observational component from 55 patients, plus separate in-vitro lymphocyte and leukocyte assays. The 55 is not a Dalargin-treated cohort.

Dose, route and schedule

Dalargin 0.1 µg/mL in the leukocyte-migration assay. A complete concentration/time protocol for the proliferation assay is not given.

Protocol source ↗ · Original indexed abstract; historical research methods

Results · Original indexed abstract; full outcome tables unavailable
MeasureResultComparison, timing and statistics
Lymphocyte proliferationIncrease or decrease depended on baseline responsiveness to phytohemagglutininBidirectional culture response; not a uniform immune stimulant
Leukocyte migrationInhibition reported with Dalargin 0.1 µg/mLCulture assay; numerical migration change unavailable
Serum correlation componentSerum from 55 patients; endogenous leu-enkephalin inversely correlated with mitogen responsivenessObservational association, not 55 patients receiving Dalargin

Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.

Source for these results ↗ · Reviewed 2026-11-08

Population / setting
Human-serum observational component from 55 patients, plus separate in-vitro lymphocyte and leukocyte assays. The 55 is not a Dalargin-treated cohort.
Source reviewed
Original PubMed / Europe PMC indexed abstract checked. Missing group sizes, doses, raw outcomes and uncertainty are not reconstructed.
Study limitations
  • In-vitro donor counts, response magnitudes and exposure duration unavailable in the abstract.
  • Observational serum results and drug-exposure experiments are different components.

Reviewed 2026-11-08.

Read the source ↗

Lab research · 1988

Effect of the synthetic endogenous opioid analog dalargin on the natural cytotoxicity of human lymphocytes

Dalargin increased NK–target binding and the proportion of active NK cells in vitro. The abstract gives concentrations but no numerical cytotoxicity effect size.

Study notes and original source
1988In vitroEnglish abstract

Effect of the synthetic endogenous opioid analog dalargin on the natural cytotoxicity of human lymphocytes

Dalargin preincubation of human lymphocytes; no Thymalin treatment. · Original journal publication

Format: Original indexed abstract · Reviewed: Indexed abstract and citation checked; full original outcome tables not recovered

Aleksandrova EN, Nasonov EL, Vinogradov VA, Titov MI · Biull Eksp Biol Med. 1988;105(4):442-445. PMID 3359025

Dalargin increased NK–target binding and the proportion of active NK cells in vitro. The abstract gives concentrations but no numerical cytotoxicity effect size.

Results and tables

Reported findings and study design

Findings described in words

Dalargin increased NK–target binding and the proportion of active NK cells in vitro. The abstract gives concentrations but no numerical cytotoxicity effect size.

Human peripheral-blood lymphocytes tested against K-562 target cells; donor and replicate counts unavailable.

Population or model Human peripheral-blood lymphocytes tested against K-562 target cells; donor and replicate counts unavailable.

Dose, route and schedule

Human lymphocytes preincubated with Dalargin 10⁻¹⁴–10⁻⁸ M; naloxone 10⁻⁶ M tested separately. Incubation duration and full dose–response table unavailable.

Protocol source ↗ · Original indexed abstract; historical research methods

Results · Original indexed abstract; full outcome tables unavailable
MeasureResultComparison, timing and statistics
NK-cell functionMore effector–target contacts and active NK cells describedK-562 laboratory target assay; no clinical cancer outcome or numerical benefit estimate
Experimental exposureDalargin preincubation at 10⁻¹⁴–10⁻⁸ MDuration unavailable; the later peak-range sentence has a malformed exponent and is not reconstructed
Naloxone findingAt 10⁻⁶ M, naloxone itself enhanced target contacts and lytic activity in this assayDifferent response from the 1987 proliferation-blockade experiment; receptor effects are assay-dependent

Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.

Source for these results ↗ · Reviewed 2026-11-08

Population / setting
Human peripheral-blood lymphocytes tested against K-562 target cells; donor and replicate counts unavailable.
Source reviewed
Original PubMed / Europe PMC indexed abstract checked. Missing group sizes, doses, raw outcomes and uncertainty are not reconstructed.
Study limitations
  • Original response curves, donor counts and route-independent safety require full text.
  • One activity-peak exponent is malformed in the indexed abstract; no corrected range is asserted.
  • Natural cytotoxicity in vitro is not anticancer efficacy.

Reviewed 2026-11-08.

Read the source ↗

Lab research · 1994

The effect of endogenous opioid peptides and their synthetic analogs on T-cell immunity

The abstract describes an opioid-class stimulation maximum when added 24–48 hours after culture initiation under suboptimal antigen conditions. It does not isolate a quantitative Dalargin-specific maximum.

Study notes and original source
1994In vitroEnglish abstract

The effect of endogenous opioid peptides and their synthetic analogs on T-cell immunity

Met-/leu-enkephalins, DAGO, DADLE and Dalargin tested as distinct opioid ligands. · Original journal publication

Format: Original indexed abstract · Reviewed: Indexed abstract and citation checked; full original outcome tables not recovered

Korostelev SA, Isakova KL, Shchegolev AI, Uteshev BS · Eksp Klin Farmakol. 1994;57(1):57-61. PMID 8142868

The abstract describes an opioid-class stimulation maximum when added 24–48 hours after culture initiation under suboptimal antigen conditions. It does not isolate a quantitative Dalargin-specific maximum.

Results and tables

Reported findings and study design

Findings described in words

The abstract describes an opioid-class stimulation maximum when added 24–48 hours after culture initiation under suboptimal antigen conditions. It does not isolate a quantitative Dalargin-specific maximum.

Alloantigen-stimulated mixed-lymphocyte cultures; species, sample counts and quantitative Dalargin-specific response unresolved in the abstract.

Population or model Alloantigen-stimulated mixed-lymphocyte cultures; species, sample counts and quantitative Dalargin-specific response unresolved in the abstract.

Dose, route and schedule

The abstract describes opioid addition 24–48 hours after culture initiation for a class-level maximum; Dalargin-specific concentration and timing are not fully resolved.

Protocol source ↗ · Original indexed abstract; historical research methods

Results · Original indexed abstract; full outcome tables unavailable
MeasureResultComparison, timing and statistics
Timing-dependent culture responseLargest opioid-class stimulation described after addition at 24–48 hoursClass-level statement under suboptimal antigen conditions; not a Dalargin-specific human schedule
Ligand differencesSelective mu- and delta-ligands had effects in different directionsDAGO and DADLE findings are not assigned to Dalargin
Dalargin-specific quantitative gapNo separate numerical Dalargin effect or concentration table provided

Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.

Source for these results ↗ · Reviewed 2026-11-08

Population / setting
Alloantigen-stimulated mixed-lymphocyte cultures; species, sample counts and quantitative Dalargin-specific response unresolved in the abstract.
Source reviewed
Original PubMed / Europe PMC indexed abstract checked. Missing group sizes, doses, raw outcomes and uncertainty are not reconstructed.
Study limitations
  • Concentrations, denominators, uncertainty and precise ligand-specific contrasts require the full paper.
  • Culture timing is not a clinical administration schedule and does not establish Thymalin combination benefit.

Reviewed 2026-11-08.

Read the source ↗

Lab research · 1994

The effect of endogenous opioid peptides and their synthetic analogs on the activity of natural killer cells

Dalargin and endogenous opioid peptides enhanced NK-cell cytolytic activity in the abstract; no numerical effect size was supplied.

Study notes and original source
1994In vitroEnglish abstract

The effect of endogenous opioid peptides and their synthetic analogs on the activity of natural killer cells

Dalargin and other opioid peptides tested separately. · Original journal publication

Format: Original indexed abstract · Reviewed: Indexed abstract and citation checked; full original outcome tables not recovered

Uteshev BS, Korostelev SA, Isakova KL, Shchegolev AI · Eksp Klin Farmakol. 1994;57(1):55-57. PMID 8142867

Dalargin and endogenous opioid peptides enhanced NK-cell cytolytic activity in the abstract; no numerical effect size was supplied.

Results and tables

Reported findings and study design

Findings described in words

Dalargin and endogenous opioid peptides enhanced NK-cell cytolytic activity in the abstract; no numerical effect size was supplied.

Natural-killer-cell culture assays; the indexed record includes mouse/animal terms, not a human treatment cohort. Sample counts unavailable.

Population or model Natural-killer-cell culture assays; the indexed record includes mouse/animal terms, not a human treatment cohort. Sample counts unavailable.

Protocol information

Dose, route and treatment schedule are not sufficiently described in the abstract.

Protocol source ↗ · Original indexed abstract; protocol unavailable

Results · Original indexed abstract; full outcome tables unavailable
MeasureResultComparison, timing and statistics
NK-cell cytolysisIncrease described with Dalargin and endogenous peptidesCell-culture endpoint, not a clinical antitumor response
Numerical extraction gapNo concentration, effect magnitude, denominator or uncertainty in the abstract

Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.

Source for these results ↗ · Reviewed 2026-11-08

Population / setting
Natural-killer-cell culture assays; the indexed record includes mouse/animal terms, not a human treatment cohort. Sample counts unavailable.
Source reviewed
Original PubMed / Europe PMC indexed abstract checked. Missing group sizes, doses, raw outcomes and uncertainty are not reconstructed.
Study limitations
  • The concentration in the 1988 human-cell assay applies only to that experiment.
  • No Thymalin combination, human treatment or cancer-survival benefit established.

Reviewed 2026-11-08.

Read the source ↗

Comparison in people · 1991

Effect of dalargin on repair capacity of gastroduodenal mucosa in patients with duodenal ulcer

After 20 days, Dalargin was associated with a higher index of DNA-synthesizing epithelial nuclei in fundal and duodenal-bulb mucosa than conventional care. No numerical index was supplied.

Study notes and original source
1991Human comparative studyEnglish abstract

Effect of dalargin on repair capacity of gastroduodenal mucosa in patients with duodenal ulcer

Dalargin compared with conventional therapy; no Thymalin coadministration established. · Original journal publication

Format: Original indexed abstract · Reviewed: Indexed abstract and citation checked; full original outcome tables not recovered

Timoshin SS, Alekseenko SA, Shtuka AA · Klin Med (Mosk). 1991;69(3):75-77. PMID 2067344

After 20 days, Dalargin was associated with a higher index of DNA-synthesizing epithelial nuclei in fundal and duodenal-bulb mucosa than conventional care. No numerical index was supplied.

Results and tables

Reported findings and study design

Findings described in words

After 20 days, Dalargin was associated with a higher index of DNA-synthesizing epithelial nuclei in fundal and duodenal-bulb mucosa than conventional care. No numerical index was supplied.

Duodenal-ulcer patients treated with Dalargin or conventional spasmolytic/antacid care; group sizes unavailable in the abstract.

Population or model Duodenal-ulcer patients treated with Dalargin or conventional spasmolytic/antacid care; group sizes unavailable in the abstract.

Dose, route and schedule

Twenty-day Dalargin course. Dose, route and administration frequency are unavailable in the abstract.

Protocol source ↗ · Original indexed abstract; historical research methods

Results · Original indexed abstract; full outcome tables unavailable
MeasureResultComparison, timing and statistics
Mucosal DNA-synthesis markerSignificant increase in labelled epithelial nuclei described after DalarginFundal and duodenal-bulb biopsies; exact indices, p-value and group sizes unavailable · 20 days
Clinical endpoint gapNo numerical ulcer-closure, relapse, symptom or safety comparison in the abstract

Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.

Source for these results ↗ · Reviewed 2026-11-08

Population / setting
Duodenal-ulcer patients treated with Dalargin or conventional spasmolytic/antacid care; group sizes unavailable in the abstract.
Source reviewed
Original PubMed / Europe PMC indexed abstract checked. Missing group sizes, doses, raw outcomes and uncertainty are not reconstructed.
Study limitations
  • Historical active comparator; allocation, masking and other ulcer care require full text.
  • A proliferation marker is not a demonstrated clinical healing or combination-treatment benefit.

Reviewed 2026-11-08.

Read the source ↗

Animal research · 2007

On the character of Dalargin’s influence on duodenal secretory epithelial cells

The paper reports phase- and tissue-dependent mucin changes: a villus mucin-production index rose from a reported baseline 60.56±4.01 to 110.2±0.75 by day 3; early crypt and trefoil responses were mixed.

Study notes and original source
2007Animal / experimentalRussian-language source

On the character of Dalargin’s influence on duodenal secretory epithelial cells

Dalargin alone; Thymalin was not tested. · Original animal journal publication

Format: Original publisher PDF indexed full text; original page images not visually inspected · Reviewed: Methods and selected numerical narrative outcomes checked in the original indexed four-page paper

V. L. Mogilnaya · Uspekhi sovremennogo estestvoznaniia. 2007;(12, part 1):33–36.

The paper reports phase- and tissue-dependent mucin changes: a villus mucin-production index rose from a reported baseline 60.56±4.01 to 110.2±0.75 by day 3; early crypt and trefoil responses were mixed.

Results and tables

Reported findings and study design

Reported findings

The paper reports phase- and tissue-dependent mucin changes: a villus mucin-production index rose from a reported baseline 60.56±4.01 to 110.2±0.75 by day 3; early crypt and trefoil responses were mixed.

Male Wistar rats, intact mucosa and experimental duodenal-ulcer conditions; three described groups, but animal counts not reported.

Population or model Male Wistar rats, intact mucosa and experimental duodenal-ulcer conditions; three described groups, but animal counts not reported.

Dose, route and schedule

Dalargin 24 µg/kg every 12 hours in the intact-animal parenteral group; the ulcer group received subcutaneous Dalargin every 12 hours without restating its dose. Intact-group assessments days 1, 2, 4 and 7; ulcer-group days 1–3. No missing ulcer-group dose is silently filled in.

Protocol source ↗ · Original methods, p.33; route and dose statements kept source-specific

Results · Original publisher PDF indexed narrative, pp.33–36; no page-image verification
MeasureResultComparison, timing and statistics
Villus mucin-production indexReported baseline 60.56±4.01; 110.2±0.75 at day 3 with DalarginHistochemical index, source-specific units; not an 82% clinical healing benefit. Original uncertainty type not defined.
Separate untreated-ulcer reference57.7±0.95 reported for villus mucin production without DalarginConclusion gives this reference separately; no matched-time treatment effect or confidence interval inferred
Crypt mucin response in ulcer conditionsNo response to Dalargin over the first three days describedNeutral location-specific finding, despite the favorable villus narrative
Intact-mucosa early crypt coefficient2.19±0.07 in controls versus 1.85±0.1 after DalarginNeutral-mucin cytochemical coefficient; an early decrease, not uniform stimulation · Day 1 · p<0.01
Trefoil-peptide signalEarly fall after Dalargin in ulcer-bearing animals, followed by return toward initial levels on days 2–3Qualitative histochemistry; no clinical consequence established

This paper extends the mucosal-repair hypothesis while showing phase- and compartment-dependent responses. It is not a Thymalin combination experiment or a quantified clinical healing trial.

Source for these results ↗ · Reviewed 2026-11-08

Population / setting
Male Wistar rats, intact mucosa and experimental duodenal-ulcer conditions; three described groups, but animal counts not reported.
Source reviewed
Original publisher indexed PDF pp.33–36, including the untreated-ulcer value and neutral/early-decrease passages. Sample sizes and the type of ± uncertainty are not established. Original PDF page images unavailable.
Study limitations
  • No animal group sizes, masking or complete statistical plan supplied.
  • Histochemical indices are surrogate tissue measures, not clinical ulcer-healing percentages.
  • The source gives both a general baseline and an untreated-ulcer reference; they are not interchangeable control time points.
  • Intact and ulcer-bearing animals show different time courses. Dose is explicitly printed for the intact group but not repeated for the ulcer group.

Reviewed 2026-11-08.

Read the source ↗

Animal research · 2016

Correction of Negative Effect of Antenatal Hypoxia on Liver Tissue Homeostasis in Newborn Albino Rats with Opioid Peptides

Neonatal Dalargin reportedly normalized liver growth/proliferation and nucleolar measures after prenatal hypoxia. The non-opioid analogue did not normalize all measures. Both reduced oxidative-stress indices; neither was administered to pregnant animals in this study.

Study notes and original source
2016Animal / experimentalEnglish abstract

Correction of Negative Effect of Antenatal Hypoxia on Liver Tissue Homeostasis in Newborn Albino Rats with Opioid Peptides

dalargin · Original journal publication

Format: Publication record and available text · Reviewed: Indexed original abstract; full methods and outcome tables not recovered

Pinaeva OG, Sazonova EN, Lebed'ko OA, Timoshin SS · Bulletin of experimental biology and medicine. 2016;162(2):203. PMID 27909965

Neonatal Dalargin reportedly normalized liver growth/proliferation and nucleolar measures after prenatal hypoxia. The non-opioid analogue did not normalize all measures. Both reduced oxidative-stress indices; neither was administered to pregnant animals in this study.

Results and tables

Reported findings and study design

Findings described in words

Neonatal Dalargin reportedly normalized liver growth/proliferation and nucleolar measures after prenatal hypoxia. The non-opioid analogue did not normalize all measures. Both reduced oxidative-stress indices; neither was administered to pregnant animals in this study.

Dalargin or a non-opiate Leu-enkephalin analogue, 100 µg/kg on postnatal days 2–6; day-7 liver growth, proliferation, nucleolar and redox assays.

Population or model Seven-day-old rats after antenatal hypoxia; peptide exposure on postnatal days 2–6; n absent from abstract

Results · Indexed original abstract; full methods and outcome tables not recovered
MeasureResultComparison, timing and statistics
DalarginReported normalization of gravimetric, proliferation and hepatocyte nucleolar measures
Non-opioid analogue: incomplete effectGravimetric and nucleolar parameters not normalized; proliferating-cell pool increasedRelated analogue is not Dalargin
Redox outcomesBoth preparations reduced free-radical oxidation and improved antioxidant defenses; numerical effects unavailable

Postnatal animal treatment, not maternal administration or human neonatal efficacy. Abstract gives no group n, exact numerical effects, comprehensive safety series or proof of normal adult liver function. The related analogue’s exact preparation must be verified separately before assigning its results to a specific NALE formulation.

Source for these results ↗ · Reviewed 2026-11-08

Population / setting
Seven-day-old rats after antenatal hypoxia; peptide exposure on postnatal days 2–6; n absent from abstract
Source reviewed
Indexed original abstract; full methods and outcome tables not recovered
Study limitations
  • Postnatal animal treatment, not maternal administration or human neonatal efficacy.
  • Abstract gives no group n, exact numerical effects, comprehensive safety series or proof of normal adult liver function.
  • The related analogue’s exact preparation must be verified separately before assigning its results to a specific NALE formulation.

Reviewed 2026-11-08.

Read the source ↗

Comparison in people · 2025

Dalargin plus carbohydrate loading during oropharyngeal cancer surgery

The combined protocol was associated with lower stress-hormone responses, more favorable aerobic-metabolism measures and fewer postoperative complications. The abstract gives no figures for these differences.

Study notes and original source
2025Human comparative studyRussian-language source

Dalargin plus carbohydrate loading during oropharyngeal cancer surgery

Dalargin during perioperative care plus preoperative carbohydrate loading · Original clinical journal publication

Format: Original publisher abstract in journal PDF · Reviewed: Publisher abstract checked; numerical outcome tables not yet extracted

D. N. Vasiliev, D. E. Kulbakin, E. L. Choynzonov, S. V. Avdeev, A. A. Lee, I. P. Puteev, A. V. Pak, A. V. Kushner · Siberian Journal of Oncology. 2025;24(1):29–38

The combined protocol was associated with lower stress-hormone responses, more favorable aerobic-metabolism measures and fewer postoperative complications. The abstract gives no figures for these differences.

Results and tables

Reported findings and study design

Findings described in words

The combined protocol was associated with lower stress-hormone responses, more favorable aerobic-metabolism measures and fewer postoperative complications. The abstract gives no figures for these differences.

58 surgical patients with oropharyngeal cancer; 29 combined-intervention and 29 standard-care patients

Results · Original publisher abstract, journal PDF p.29; full tables not yet extracted
MeasureResultComparison, timing and statistics
Stress-hormone response and metabolismLower stress-hormone release and more favorable aerobic-metabolism measures reported with the combined protocolDalargin plus carbohydrate loading versus standard perioperative care; numerical changes not available in the abstract · Perioperative assessments
Postoperative complicationsFewer complications reported; counts, types and effect uncertainty not extractedNo numerical risk reduction inferred
Study groups29 combined-intervention versus 29 standard-care patients; 58 total

A combined perioperative intervention, not isolated Dalargin efficacy or an anticancer trial. Reported differences remain qualitative until outcome tables can be checked.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
58 surgical patients with oropharyngeal cancer; 29 combined-intervention and 29 standard-care patients
Source reviewed
Original journal abstract; no complete risk-of-bias appraisal or verification of full outcome tables.
Study limitations
  • Dalargin was combined with carbohydrate loading; the independent contribution of each is unresolved.
  • Randomization, masking and allocation concealment were not established in the abstract.
  • Numerical complication counts, effect sizes and uncertainty require the original outcome tables.
  • Perioperative metabolic findings do not demonstrate improved tumor control or cancer survival.

Reviewed 2026-11-06.

Read the source ↗

Experiment described in a patent · 2024

Dalargin: menopausal symptoms and six-month follow-up — RU2821826C1

The inventor reports symptom improvement after Dalargin with persistence at six months. Pineamin and IPH GAA are background references, not treatments in this comparison.

Reported clinical improvement · 15/15 (100%) with Dalargin versus 5/8 (62.5%) with placebo · Broad symptom-based outcome; no prespecified responder threshold reported · After the 30-day course

Study notes and original source
2024Patent / reported experimentsFull text available

Dalargin: menopausal symptoms and six-month follow-up — RU2821826C1

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

Борис Юльевич Чебураков · RU2821826C1 · patent family RU2821826C1

The inventor reports symptom improvement after Dalargin with persistence at six months. Pineamin and IPH GAA are background references, not treatments in this comparison.

Results and tables

Reported patent results

Reported findings

The inventor reports symptom improvement after Dalargin with persistence at six months. Pineamin and IPH GAA are background references, not treatments in this comparison.

Patent report of 23 women aged 45–55: Dalargin n=15 versus saline placebo n=8, treated for 30 days in 2022–2024. Randomization and masking are not described.

Population or model Patent report of 23 women aged 45–55: Dalargin n=15 versus saline placebo n=8, treated for 30 days in 2022–2024. Randomization and masking are not described.

Results · Description: 2022–2024 comparison and Example 1; original Russian and indexed English text.
MeasureResultComparison, timing and statistics
Reported clinical improvement15/15 (100%) with Dalargin versus 5/8 (62.5%) with placeboBroad symptom-based outcome; no prespecified responder threshold reported · After the 30-day course
Six-month follow-upAll 15 Dalargin recipients reportedly retained improvement; all 8 placebo recipients returned to baselineFollow-up completeness and independent assessment not established · 6 months
Illustrative patient: hot flashes15–20/day at baseline, 3–5/day at day 15, absent at day 30One 54-year-old patient; not a group mean · Days 15 and 30; benefit reported at 6 months
Reported tolerabilityNo complications or side effects reportedSmall patent series; systematic adverse-event ascertainment not described

Unequal small groups, undefined improvement criteria, no documented allocation concealment or blinding, and no statistical estimates. These are inventor-reported observations, not established efficacy. The unrelated IPH GAA percentages are not Dalargin or Pineamin results.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Patent report of 23 women aged 45–55: Dalargin n=15 versus saline placebo n=8, treated for 30 days in 2022–2024. Randomization and masking are not described.
Source reviewed
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
  • The small unequal groups, undefined response criteria and unverified allocation and masking prevent an established treatment effect.
  • Unequal small groups, undefined improvement criteria, no documented allocation concealment or blinding, and no statistical estimates. These are inventor-reported observations, not established efficacy. The unrelated IPH GAA percentages are not Dalargin or Pineamin results.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-06.

Read the source ↗

Experiment described in a patent · 2021

Dalargin: nasal respiratory-infection use and formulation — EP3556377B1

The patent reports reduced stimulated inflammatory-cytokine production and altered innate-cell activity.

Donor-cell cytokines · Reduced stimulated IL-1, IL-6 and TNF-α production reported · In-vitro experiment using cells from 20 donors; exact figure percentages not transcribed

Study notes and original source
2021Patent / reported experimentsFull text available

Dalargin: nasal respiratory-infection use and formulation — EP3556377B1

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

Evgeny Alexandrovich Chertorizhsky, Mikhail Vladimirovich Ovchinnikov, Aleksey Viktorovich Kleimenov · EP3556377B1 · patent family 64328036

The patent reports reduced stimulated inflammatory-cytokine production and altered innate-cell activity.

Results and tables

Reported patent results

Findings described in words

The patent reports reduced stimulated inflammatory-cytokine production and altered innate-cell activity.

Dalargin preclinical immune/inflammatory experiments, including cells from 20 healthy donors; these donors did not receive the proposed treatment.

Population or model Dalargin preclinical immune/inflammatory experiments, including cells from 20 healthy donors; these donors did not receive the proposed treatment.

Results · Donor-cell cytokine experiment and Figure 3; animal phagocyte narrative.
MeasureResultComparison, timing and statistics
Donor-cell cytokinesReduced stimulated IL-1, IL-6 and TNF-α production reportedIn-vitro experiment using cells from 20 donors; exact figure percentages not transcribed
Animal innate-cell findingsIncreased phagocytic activity described; no detected difference between the tested routesA laboratory result, not demonstrated clinical infection recovery

Human-derived cells are not a human treatment trial. Cytokine and cell-function results cannot establish clinical antiviral effectiveness, route equivalence or safety.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Dalargin preclinical immune/inflammatory experiments, including cells from 20 healthy donors; these donors did not receive the proposed treatment.
Source reviewed
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
  • A granted formulation or use claim does not establish clinical antiviral benefit.
  • Human-derived cells are not a human treatment trial. Cytokine and cell-function results cannot establish clinical antiviral effectiveness, route equivalence or safety.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-06.

Read the source ↗

Experiment described in a patent · 2011

GHK plus Dalargin: 2011 bone-repair patent — RU2429002C1

The authors describe more advanced early bone repair with GHK plus Dalargin than with saline or either peptide alone. The evidence is qualitative radiography and histology.

Study notes and original source
2011Patent / reported experimentsFull text available

GHK plus Dalargin: 2011 bone-repair patent — RU2429002C1

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

Виктор Юрьевич Чердаков, Михаил Юрьевич Смахтин, Григорий Михайлович Дубровин, Игорь Иванович Бобынцев, Виктор Тарасович Дудка, Максим Евгеньевич Долгинцев, Алексей Анатольевич Крюков, Вадим Теймуразович Корошвили, Ирина Михайловна Соболева, Евгений Николаевич Кононец, Андрей Евгеньевич Белых, Ольга Игоревна Иванова · RU2429002C1 · patent family 44758621

The authors describe more advanced early bone repair with GHK plus Dalargin than with saline or either peptide alone. The evidence is qualitative radiography and histology.

Results and tables

Reported patent results

Findings described in words

The authors describe more advanced early bone repair with GHK plus Dalargin than with saline or either peptide alone. The evidence is qualitative radiography and histology.

Wistar rat fracture model; groups of 8–10 animals; saline, copper-free GHK, Dalargin and combined treatment; assessment at day 10.

Results · Original patent description, figure captions and experimental example; images not independently scored.
MeasureResultComparison, timing and statistics
Combined treatment: radiographic appearanceFracture line described as barely visible with the combination; still visible but less pronounced with either peptide aloneVersus saline and single-peptide groups; no numerical radiographic score or uncertainty reported · Day 10
Combined treatment: histological appearanceNew bone formation and remodeling toward compact bone were described as more advanced in the combination groupDescriptive morphology; no quantitative histomorphometry or factorial interaction test · Day 10
GHK versus Dalargin aloneNo visible morphological difference reported between the two single-peptide groupsA neutral qualitative comparison, not a demonstration of equivalence · Day 10
Healing time, strength and safetyNo measured union-time advantage, biomechanical strength estimate or formal adverse-event series reportedA day-10 observation does not mean fractures healed ten days faster
Reported group sizes8–10 rats per group; exact group denominators not assigned
Reported experimental courseDaily GHK plus Dalargin for ten days; other groups received single peptides or saline

Early rat bone-repair observations do not establish clinical fracture healing or quantitatively validated synergy. The preparation was copper-free GHK plus Dalargin. Related author publications may reuse the research program.

Source for these results ↗ · Reviewed 2026-11-07

Population / setting
Wistar rat fracture model; groups of 8–10 animals; saline, copper-free GHK, Dalargin and combined treatment; assessment at day 10.
Source reviewed
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
  • The fracture experiment tested the combination in rats. No measured shortening of healing time or biomechanical strength was reported.
  • Early rat bone-repair observations do not establish clinical fracture healing or quantitatively validated synergy. The preparation was copper-free GHK plus Dalargin. Related author publications may reuse the research program.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-07.

Read the source ↗

Experiment described in a patent · 1991

Immune-profile-directed peptide selection with psoriasis photochemotherapy — SU1674849A1

The patent chose alternative peptides for opposing lymphocyte profiles. Case immune measures changed during combined care; no simultaneous Thymalin–Dalargin regimen was established.

Study notes and original source
1991Patent / reported experimentsFull text available

Immune-profile-directed peptide selection with psoriasis photochemotherapy — SU1674849A1

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

I. O. Malova, R. G. Skvortsova, N. P. Kuznetsova · SU1674849A1 · patent family 21434935

The patent chose alternative peptides for opposing lymphocyte profiles. Case immune measures changed during combined care; no simultaneous Thymalin–Dalargin regimen was established.

Results and tables

Reported patent results

Reported findings

The patent chose alternative peptides for opposing lymphocyte profiles. Case immune measures changed during combined care; no simultaneous Thymalin–Dalargin regimen was established.

Three disclosed individual psoriasis cases, each receiving a different peptide alongside photochemotherapy; these are not controlled treatment groups.

Population or model Three disclosed individual psoriasis cases, each receiving a different peptide alongside photochemotherapy; these are not controlled treatment groups.

Results · Original Russian patent text as indexed, three selected examples; scan and aggregate table not recovered
MeasureResultComparison, timing and statistics
Alternative-treatment examplesDalargin case B cells 10%→20%; Thymalin case 32%→13%; T-activin case 28.6%→14%One selected patient per peptide, with photochemotherapy; changes are not comparative treatment effects
Dalargin case: immune measuresT-suppressor index 9%→25%; T-helper index 71%→55%Example 2; B cells 10%→20%; historical subset methods are not modern Treg measurements
Thymalin case: immune measuresT-suppressor index 33%→30%; T-helper index 35%→57%Example 3; B cells 32%→13%
T-activin case: immune measuresT-suppressor index 40%→34%; T-helper index 31.4%→52%Example 1; B cells 28.6%→14%
Clinical course in selected casesDischarge reported on day 19 with Dalargin and day 21 with Thymalin or T-activinIndividual clinical descriptions; no matched control or causal days-saved estimate
Russian-text peptide schedulesDalargin 1 mg intramuscularly twice daily for 5 days; Thymalin 5 mg intramuscularly once daily for 4 days; or T-activin 50 µg subcutaneously daily for 5 daysAlternative historical treatments with photochemotherapy, not a combined or current prescribing regimen
Translation and extraction gapsEnglish abstract mistranslates T-activin as 50 mg; one Thymalin case mistranslates frequency as four times dailyRussian text and course totals specify 50 µg and once daily, respectively. Patent PDF and aggregate comparison table not recovered.
Three selected patent cases: before → after
Three selected patent cases: before → after
Historical immune measureDalargin, example 2Thymalin, example 3T-activin, example 1
B-lymphocytes (%)10→2032→1328.6→14
T-suppressor index (%)9→2533→3040→34
T-helper index (%)71→5535→5731.4→52

Case descriptions, not study-arm means; n=1 selected patient per preparation. Photochemotherapy was concurrent. Historical subset labels do not establish modern regulatory-T-cell phenotypes.

This patent supports an early hypothesis of immune-profile-dependent peptide selection, not Thymalin–Dalargin synergy. The before/after changes cannot isolate peptide effects from photochemotherapy, natural fluctuation or selection of favorable cases.

Source for these results ↗ · Reviewed 2026-11-08

Population / setting
Three disclosed individual psoriasis cases, each receiving a different peptide alongside photochemotherapy; these are not controlled treatment groups.
Source reviewed
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
  • Selected case reports with photochemotherapy and historical immune assays; no controlled pair trial or isolated peptide effect. Russian dose/frequency statements are distinguished from mistranslated English text.
  • This patent supports an early hypothesis of immune-profile-dependent peptide selection, not Thymalin–Dalargin synergy. The before/after changes cannot isolate peptide effects from photochemotherapy, natural fluctuation or selection of favorable cases.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-08.

Read the source ↗

Animal research · 2020

PPK-V versus Cortexin, Semax and Dalargin: rat peptide-profile study

Hypoxia and swimming results came from separate animal cohorts. The original raw times and dose statements are retained below.

Study notes and original source
2020Animal / experimentalFull text available

PPK-V versus Cortexin, Semax and Dalargin: rat peptide-profile study

Commercial Cortexin, Semax and Dalargin; their combinations; experimental calf-brain hydrolysates PPK-A, B, V, G, D and E. PPK-V is cortex-derived; PPK-B is brainstem-derived. · Original animal and analytical journal research

Format: Original publisher indexed HTML/PDF text; matching tables in recovered 2019 monograph · Reviewed: Original indexed methods and Tables 1–7 checked; matching monograph pp.294–296 visually inspected. Original journal PDF page images not recovered.

E. B. Shustov, D. Yu. Ivkin, A. S. Ivkina, A. E. Kim, S. L. Lublin, M. S. Nesterov · Search for the optimal mass profile of neuropeptides for the implementation of antihypoxic and activating actions. Pharmacy Formulas. 2020;2(4):72–81.

Table 2 reports PPK-V hypoxia time 552±44 s and swimming time 289±66 s; Cortexin 201±11 s and 172±44 s; displayed controls 95±3 s and 135±6 s. Unequal doses and pooled experiments prevent a reliable potency or superiority claim.

Results and tables

Reported findings and study design

Reported findings

Raw times and standardized T-scores are shown separately below. Larger reported values are not a dose-matched estimate of superiority.

Ten rats per group; males for chamber hypoxia (time to agonal signs) and females for loaded swimming (time to exhaustion). Single rectal exposure one hour before testing; saline vehicle controls. Separately performed experiments were standardized and pooled.

Population or model Outbred rats; ten per treatment group and separate control groups for each endpoint. Hypoxia: three-month-old males, 250±20 g. Loaded swimming: pretrained females, 200±20 g. A pooled analysis of separate experiments, not a verified single contemporaneous head-to-head cohort.

Dose, route and schedule

Single rectal administration one hour before testing. Methods list Dalargin 0.56 mg/kg, Semax 0.22 mg/kg, Cortexin 1 mg/kg and experimental peptide preparations 2.5 mg/kg. Combination components were not dose-reduced. The discussion instead gives an overall range up to 8.06 mg/kg for PPK-E; this discrepancy is unresolved.

Protocol source ↗ · Original methods and dose-analysis discussion; animal protocol, not human dosing

Results · Original publisher indexed text, methods and selected Tables 1, 2, 5 and 6; matching monograph Tables 109–110 visually checked
MeasureResultComparison, timing and statistics
PPK-V: hypoxia time552±44 s; Cortexin 201±11 s; displayed control 95±3 sTable 2, M±m; separate experiments and unequal doses; no verified pairwise PPK-V-versus-Cortexin p-value
PPK-V: loaded-swimming time289±66 s; Cortexin 172±44 s; displayed control 135±6 sTable 2, M±m; 10% body-weight load; female cohort differs from the male hypoxia cohort
Route, timing and nominal PPK doseRectal, once, one hour before testing; experimental preparations 2.5 mg/kg in methodsDiscussion maximum: 8.06 mg/kg for PPK-E; individual complex exposures not fully reconciled
Cortexin aloneHypoxia 201±11 s; loaded swimming 172±44 sDisplayed controls 95±3 s and 135±6 s; M±m; methods dose 1 mg/kg rectally
Semax aloneHypoxia 218±23 s; loaded swimming 221±60 sDisplayed controls 95±3 s and 135±6 s; M±m; methods dose 0.22 mg/kg rectally
Dalargin aloneHypoxia 170±8 s; loaded swimming 201±12 sDisplayed controls 95±3 s and 135±6 s; M±m; methods dose 0.56 mg/kg rectally
Combination comparisonsCortexin + Dalargin: 250±15 s / 275±62 s; Semax + Dalargin: 293±25 s / 198±10 sHypoxia / swimming; M±m. Components were not dose-reduced. The combined Semax/Dalargin swimming mean was below Semax alone (221±60 s); no formal synergy demonstrated.
5–10 kDa fraction and hypoxiaD=0.44; p=10⁻²⁰Table 5 pooled factor analysis; association does not identify the active molecule or establish causation
5–10 kDa fraction and swimmingD=0.01; p=0.97Table 6: no association detected in this analysis; the hypoxia finding is not a general performance result
Dose as a confounding factorReported dose-factor D=0.31 for hypoxia and D=0.40 for swimmingTable 4; composition and exposure varied together. The authors grouped doses across different preparations.
Mass-profile reporting gapPPK-V fractions total 95.33%; Cortexin fractions total 98.37%Calculated sums of Table 1 entries, not new laboratory results. Final bin heading >1 kDa conflicts with the narrative <1 kDa; no renormalization.
Safety and durationNo dedicated adverse-event counts, long-term follow-up or human PPK-V outcome suppliedAn acute functional assay cannot establish a safe human regimen
Table 2: raw times and T-scores kept separate
Table 2: raw times and T-scores kept separate
PreparationHypoxia time (s), M±mHypoxia T-score, M±mSwimming time (s), M±mSwimming T-score, M±m
Saline control95±350±1135±650±2
Dalargin170±879±3201±12331±38
Semax218±2397±9221±60397±198
Cortexin201±1191±4172±44235±143
Cortexin + Dalargin250±15110±5275±62576±202
Semax + Dalargin293±25126±10198±10319±33
PPK-A · hippocampus532±47418±128309±71684±233
PPK-B · brainstem538±23418±73186±27280±90
PPK-V · cortex552±44460±130289±66621±215
PPK-G · combined regions551±46456±135373±95896±311
PPK-D · combined regions498±30298±87369±92886±300
PPK-E · combined regions487±22267±67344±61800±200

Original Table 2, p.76; matching 2019 monograph Table 110, p.296, visually inspected. n=10 per experimental group; separate sex-specific endpoint cohorts. Hypoxia time ends at agonal signs, not long-term survival; swimming time ends at exhaustion. Source M±m notation retained. Experiment-specific control normalization means T-score percentages are not raw-time improvements. No pairwise superiority p-values supplied here.

Table 1: reported mass-bin fractions
Table 1: reported mass-bin fractions
Preparation10–30 kDa (%)5–10 kDa (%)1–5 kDa (%)Final bin (%)
Dalargin———98
Semax———100
Cortexin—33.37623
Cortexin + Dalargin—51877
Semax + Dalargin——75.5524
PPK-A14.8838.7339.114.77
PPK-B2.5443.549.044.92
PPK-V11.3935.3943.155.4
PPK-G3036.2725.515.58
PPK-D13.8325.6323.5435.48
PPK-E12.720.2348.8718.2

Original Table 1, p.76; matching monograph Table 109, p.295, visually inspected. Final heading is printed >1 kDa, although the narrative describes <1 kDa; unresolved source inconsistency. — means a blank source cell, not verified zero. Fractions are not forced to total 100%. Molecular-mass bins do not identify peptide sequences or brain uptake.

This is a composition–activity hypothesis from pooled animal experiments. PPK-V is a distinct experimental cortex hydrolysate, not Cortexin or the brainstem PPK-B. Unequal exposures, source inconsistencies and matching earlier tables limit comparisons. No clinical superiority, formal combination synergy or intranasal PPK-V delivery has been established.

Source for these results ↗ · Reviewed 2026-11-08

Population / setting
Outbred rats; ten per treatment group and separate control groups for each endpoint. Hypoxia: three-month-old males, 250±20 g. Loaded swimming: pretrained females, 200±20 g. A pooled analysis of separate experiments, not a verified single contemporaneous head-to-head cohort.
Source reviewed
The journal text and 2019 monograph reproduce the same outcomes and mass profiles (journal Tables 1–2 and book Tables 109–110, pp. 295–296). They represent one research program. Journal page images were unavailable for comparison.
Study limitations
  • Different-sex cohorts and separate experiments contributed to the two endpoints; randomization is stated, but masking, allocation concealment and complete animal flow are not established.
  • Doses were unequal, and the nominal experimental-preparation dose in methods conflicts with the discussion maximum. Table 2 does not resolve each complex’s actual exposure.
  • Table 2 reports M±m; its uncertainty notation is retained without relabeling it as a verified SD. No preparation-specific pairwise p-values or confidence intervals establish PPK-V superiority over Cortexin.
  • T-scores standardize results against experiment-specific controls. Their percentages and ratios cannot be interpreted as proportional increases in raw swim time or clinical performance.
  • Table 1’s final bin is printed >1 kDa, while the narrative describes <1 kDa. Some fractions do not sum to 100%; blank cells are not assumed zero and values are not renormalized.
  • The 5–10 kDa association is observational within the pooled analysis, not isolation of an active sequence or proof of brain penetration. Rectal results do not establish intranasal delivery.
  • Matching 2019 and 2020 numerical tables are treated as one research program. No human PPK-V efficacy or long-term safety follows from these results.

Reviewed 2026-11-08.

Read the source ↗

Animal research · 2021

GHK, Dalargin and Thymogen in experimental bone fracture: 2021 rat study

At day 10, GHK plus Dalargin had a phagocytic index of 71.3±5.1% versus 30.8±3.1% in fracture controls. GHK alone did not significantly improve oxygen-dependent neutrophil reserve. Bone-repair findings were qualitative.

Study notes and original source
2021Animal / experimentalRussian-language source

GHK, Dalargin and Thymogen in experimental bone fracture: 2021 rat study

Copper-free GHK, Dalargin and Thymogen, singly and in pairs; local intraosseous administration · Original preclinical journal study; not a literature review

Format: Repository copy of the original nine-page journal article · Reviewed: Methods and results text checked; Table 1 (p.64) and Figure 5 (p.65) visually verified against rendered PDF pages

M. Yu. Smakhtin, I. I. Bobyntsev, V. T. Dudka, V. Yu. Cherdakov, A. O. Vorvul, A. A. Chulanova, A. M. Smakhtina · Humans and their Health / Chelovek i ego zdorovye. 2021;24(4):59–67

At day 10, GHK plus Dalargin had a phagocytic index of 71.3±5.1% versus 30.8±3.1% in fracture controls. GHK alone did not significantly improve oxygen-dependent neutrophil reserve. Bone-repair findings were qualitative.

Results and tables

Reported findings and study design

Reported findings

Pairwise GHK combinations improved phagocytosis measures in fractured rats. GHK plus Dalargin also showed the strongest oxygen-dependent reserve pattern; GHK alone had a neutral reserve result. Bone repair was assessed descriptively.

Male Wistar rats with experimental femoral fracture; Table 1 lists eight groups, n=8/group; overall cohort flow not separately specified. Eight displayed groups: uninjured saline, fractured saline, three single peptides and three pairwise combinations. Assessments at day 10; local intraosseous exposure.

Dose, route and schedule

Ten-day local intraosseous exposure in the rat study: GHK and Thymogen 0.5 µg/kg, Dalargin 1.2 µg/kg, singly or in pairs. Experimental methods, not a human regimen.

Protocol source ↗ · Original journal PDF, p.60

Results · Original journal PDF pp.60–65; Table 1 and Figure 5 visually checked
MeasureResultComparison, timing and statistics
Phagocytic index: GHK plus Dalargin71.3 ± 5.1% versus 30.8 ± 3.1% in fracture controlsUninjured control 70.7 ± 7.0%; n=8/group; M±m as printed · Day 10 · p<0.05 versus fracture control; Table 1 marks *2
Phagocytosis activation index: GHK plus Dalargin2.4 ± 0.3 versus 0.4 ± 0.03 in fracture controlsUninjured control 2.7 ± 0.2; GHK alone 1.2 ± 0.1; Dalargin alone 1.3 ± 0.1 · Day 10 · p<0.05 versus fracture control; pairwise superiority to single peptides not established by table symbols
Oxygen-dependent reserve: GHK aloneNo significant increase versus fracture controls; remained below the uninjured referenceFigure 5 group 2 has no fracture-control significance star; no exact bar values digitized · Day 10 · Figure marker indicates p<0.05 versus uninjured animals
Oxygen-dependent reserve: GHK plus DalarginIncreased versus fracture controls; not marked different from the uninjured referenceFigure 5 group 5; this does not establish equivalence to healthy animals · Day 10 · p<0.05 versus fracture control; exact plotted values not extracted
GHK plus Thymogen: phagocytic index75.3 ± 5.9% versus 30.8 ± 3.1% in fracture controlsThis combination also improved uptake; its oxygen-dependent reserve did not show the same restoration pattern as GHK plus Dalargin · Day 10 · p<0.05 versus fracture control; Table 1
Bone repairMore advanced callus remodeling described with GHK combinations; fracture line described as barely visibleQualitative histology/radiography, not a quantified union-time or strength endpoint · Day 10
Safety and clinical outcomesNo formal adverse-event series, infection-rate reduction or human treatment outcome reported
Assay group sizesTable 1 and Figure 5 report n=8/group; histology sample flow not separately established
Table 1: all reported neutrophil phagocytosis results
Table 1: all reported neutrophil phagocytosis results
GroupPhagocytic index (%)Phagocytic numberPhagocytosis activation index
Uninjured saline control70.7 ± 7.04.0 ± 0.32.7 ± 0.2
Fracture + saline30.8 ± 3.1 *11.3 ± 0.1 *10.4 ± 0.03 *1
Fracture + GHK40.7 ± 3.2 *1,22.7 ± 0.2 *1,21.2 ± 0.1 *1,2
Fracture + Dalargin40.5 ± 3.0 *1,22.7 ± 0.2 *1,21.3 ± 0.1 *1,2
Fracture + Thymogen53.2 ± 4.1 *1,22.8 ± 0.2 *1,21.7 ± 0.1 *1,2
Fracture + GHK/Dalargin71.3 ± 5.1 *23.9 ± 0.3 *22.4 ± 0.3 *2
Fracture + GHK/Thymogen75.3 ± 5.9 *24.0 ± 0.3 *22.6 ± 0.2 *2
Fracture + Thymogen/Dalargin54.6 ± 5.1 *1,22.8 ± 0.2 *1,21.8 ± 0.1 *1,2

Original M±m notation; n=8/group, day 10. *1: p<0.05 versus uninjured animals; *2: p<0.05 versus fracture/saline control. Marks retain the original comparison groups. Missing *1 is not proof of equivalence, and these are not monotherapy-versus-combination tests.

This is an original animal study, not a clinical review. Neutrophil uptake and oxygen-dependent reserve are surrogate assays; bone outcomes are descriptive. The claimed synergy lacks a formal interaction test. The 2021 local-delivery study and the 2011 systemic patent belong to a related research program; independent replication or shared animals cannot be established from the available reports.

Source for these results ↗ · Reviewed 2026-11-07

Population / setting
Male Wistar rats with experimental femoral fracture; Table 1 lists eight groups, n=8/group; overall cohort flow not separately specified
Source reviewed
Original PDF recovered through CyberLeninka and checked against publisher-deposited Crossref metadata and the Russian Central Scientific Medical Library abstract. Selected methods, results, Table 1 and Figure 5 reviewed; no independent experimental audit. Received 25 September and accepted 20 December 2021; exact publication day not established.
Study limitations
  • Small animal groups; randomization, blinded assessment, power calculation and complete participant flow are not described.
  • The numerical endpoints are neutrophil assays, not fracture-union time, mechanical bone strength or clinical infection rates.
  • Table significance symbols compare uninjured or fracture controls; they do not establish equivalence to healthy animals or a formal combination-interaction effect.
  • Local intraosseous administration differs from the systemic 2011 patent experiment. Shared authors and related models do not establish independent replication; cohort overlap is unresolved.
  • The peptide tested was unbound GHK, not GHK-Cu. Pairwise combinations used two peptides per group. The study had no three-peptide cocktail.

Reviewed 2026-11-07.

Read the source ↗

Randomized study in people · 2017

[THE INFLUENCE OF DEFICIT OF ENDOGENOUS NEUROPEPTIDES ON THE CLINICAL COURSE OF CORONARY HEART DISEASE].

Dalargin added to standard care was associated with larger changes in inflammatory and metabolic blood markers than standard care alone. Clinical cardiovascular events were not the reported endpoint.

Insulin change · −22.4% versus −6.5% · Dalargin + standard care versus standard care · 3 months · p<0.001 for Dalargin changes; p<0.05 for standard-care changes

Study notes and original source
2017Randomized trialEnglish abstract

[THE INFLUENCE OF DEFICIT OF ENDOGENOUS NEUROPEPTIDES ON THE CLINICAL COURSE OF CORONARY HEART DISEASE].

Dontsov AV · Klinicheskaia meditsina

Dalargin added to standard care was associated with larger changes in inflammatory and metabolic blood markers than standard care alone. Clinical cardiovascular events were not the reported endpoint.

Results and tables

Reported findings and study design

Dalargin added to standard care was associated with larger changes in inflammatory and metabolic blood markers than standard care alone. Clinical cardiovascular events were not the reported endpoint.

123 coronary-heart-disease patients with metabolic syndrome randomized to standard care (63) or adjunctive Dalargin (60); 84 additional CHD patients without metabolic syndrome formed a separate comparison group.

Population or model 123 patients with coronary heart disease and metabolic syndrome, randomized 63/60; an additional 84-patient comparison group without metabolic syndrome

Dose, route and schedule

2 mg/day for ten days, with three courses during three months; route not specified in the indexed abstract.

Protocol source ↗ · Indexed abstract

Results · Primary-publication indexed abstract; no full-text table appraisal
MeasureResultComparison, timing and statistics
Insulin change−22.4% versus −6.5%Dalargin + standard care versus standard care · 3 months · p<0.001 for Dalargin changes; p<0.05 for standard-care changes
TNF-α change−55% versus −9.4%Same randomized treatment groups · 3 months
IL-6 change−56.3% versus −6.1%Same groups · 3 months
Triglyceride change−27.2% versus −17.4%Same groups · 3 months
HDL cholesterol change+17.4% versus +10.3%Same groups · 3 months
Other Dalargin-arm changesβ-endorphin +32.6%; leptin −36.1%; cortisol −23.9%; LDL cholesterol −14%Within-arm changes; not placebo-adjusted effects · 3 months · p<0.001 reported
Studied schedule2 mg/day for 10 days; 3 courses across 3 monthsReported study regimen

Percentages are within-group changes. The abstract does not provide the interaction test, event rates or a cardiovascular risk reduction.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
123 patients with coronary heart disease and metabolic syndrome, randomized 63/60; an additional 84-patient comparison group without metabolic syndrome
Source reviewed
Publication metadata and indexed abstract checked through Europe PMC on 28 October 2026; full text not appraised.
Study limitations
  • Biomarker outcomes do not establish fewer cardiovascular events. Blinding and allocation concealment are not described in the abstract.
  • Abstract only. Full methods, sample-size details and adverse-event tables were outside the review.

Reviewed 2026-11-01.

Read the source ↗

Research record · 2026

Dal-PROTECT: prevention of organ dysfunction after high-risk abdominal surgery

The phase III registry lists the randomized placebo-controlled trial as completed on 10 September 2026. No results are posted as of 11 October. The primary outcome is a seven-day composite of major postoperative complications.

Study notes and original source
2026Study design unresolvedBibliographic record

Dal-PROTECT: prevention of organ dysfunction after high-risk abdominal surgery

· Clinical trial registry; results not posted

Format: Registry record · Reviewed: Registry fields checked

Botkin Hospital · ClinicalTrials.gov NCT07404358; updated 23 September 2026

The phase III registry lists the randomized placebo-controlled trial as completed on 10 September 2026. No results are posted as of 11 October. The primary outcome is a seven-day composite of major postoperative complications.

Population / setting
200 participants; registry reports actual enrollment
Source reviewed
ClinicalTrials.gov API checked: status, enrollment, intervention, outcomes and absence of results.
Study limitations
  • Completed status is not evidence of efficacy. The proposed reduction from 35% to 20% was a sample-size assumption, not an observed result.
  • Registration was first posted in February 2026, after the May 2025 study start. Registry information is sponsor-reported.

Reviewed 2026-10-11.

Read the source ↗

Animal research · 2026

Opioid receptor agonist dalargin prevents stress-induced cardiac injury and improves myocardial pump function

In female rats under 24-hour stress, Dalargin lowered serum CK-MB by 27% versus stressed controls. Partial pump-function recovery was reported without a numerical treated-group estimate; the model itself doubled end-systolic volume and lowered ejection fraction 27%.

Study notes and original source
2026Animal / experimentalEnglish abstract

Opioid receptor agonist dalargin prevents stress-induced cardiac injury and improves myocardial pump function

B. K. Kurbatov, M. Kilin, A. O. Venichenko, A. A. Boshchenko, S. V. Gusakova, L. N. Maslov · Bulletin of Experimental Biology and Medicine. 2026;182(8):129–133.

In female rats under 24-hour stress, Dalargin lowered serum CK-MB by 27% versus stressed controls. Partial pump-function recovery was reported without a numerical treated-group estimate; the model itself doubled end-systolic volume and lowered ejection fraction 27%.

Results and tables

Reported findings and study design

Reported findings

Dalargin reduced the serum CK-MB injury marker by 27% versus stressed controls; partial improvement in cardiac pump function was described.

Female Wistar rats under 24-hour immobilization stress; Dalargin versus stressed controls. Group sizes, precision estimates and p-values not supplied by the publisher abstract.

Population or model Female Wistar rats exposed to 24-hour immobilization

Dose, route and schedule

0.125 mg/kg intraperitoneally, 30 minutes before immobilization and 8 and 16 hours after its onset. Experimental animal regimen, not a human dose.

Protocol source ↗ · Publisher bilingual abstract

Results · Original publisher Russian and English abstracts
MeasureResultComparison, timing and statistics
Cardiac injury marker CK-MB27% lower with Dalargin than stressed controlsAnimal biomarker comparison, not a clinical event reduction · 24-hour stress model · No p-value or confidence interval supplied in the abstract
Pump-function response to DalarginPartial reversal reported; numerical treated-versus-stress functional estimates not provided
Stress model changes, not Dalargin effectsEnd-systolic volume doubled and left-ventricular ejection fraction fell 27%Stress versus unstressed baseline/control; these figures must not be presented as treatment improvements
Reported animal protocol0.125 mg/kg intraperitoneally, before and twice during the stress periodExperimental regimen; not clinical administration advice

Preclinical stress-injury model. No evidence here for human stress cardiomyopathy treatment or reduced cardiovascular events.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Female Wistar rats exposed to 24-hour immobilization
Source reviewed
Original publisher Russian and English abstracts; treatment effects separated from stress-model changes. Group sizes, uncertainty and full methods not verified.
Study limitations
  • Animal stress model; this does not establish cardioprotection in people.
  • Sample size, masking and full statistical methods require the complete paper.

Reviewed 2026-11-06.

Read the source ↗

Animal research · 2014

GHK, Dalargin and Thymogen in rat fracture: 2014 neutrophil results

After ten days, 69.17% of neutrophils took up latex particles with GHK + Dalargin and 72.17% with GHK + Thymogen versus 31.67% with fracture plus saline.

Study notes and original source
2014Animal / experimentalRussian-language source

GHK, Dalargin and Thymogen in rat fracture: 2014 neutrophil results

Unbound GHK, Dalargin and Thymogen given alone or in pairwise groups. · Conference proceedings paper

M. Yu. Smakhtin, G. M. Dubrovin, V. Yu. Cherdakov, Yu. V. Furman · Innovations in Medicine, Kursk State Medical University conference proceedings. 2014; pp. 256–258.

After ten days, 69.17% of neutrophils took up latex particles with GHK + Dalargin and 72.17% with GHK + Thymogen versus 31.67% with fracture plus saline.

Results and tables

Reported findings and study design

The researchers fixed a closed right femoral fracture with an intramedullary wire. After ten days they measured neutrophil uptake of latex particles, counting 100 cells per smear.

Population or model Wistar rats (180–220 g) in a closed femoral fracture model. Table 1 lists eight groups with eight rats per group, including uninjured and fractured controls.

Dose, route and schedule

Intraperitoneal treatment from the day of fracture for 10 days. Unbound GHK and Thymogen at 0.5 µg/kg each and Dalargin at 1.2 µg/kg, alone or in pairs. Fracture controls received an equivalent volume of saline.

Protocol source ↗ · Original proceedings paper, methods and Table 1.

Results · Original proceedings paper, methods and Table 1.
MeasureResultComparison, timing and statistics
Neutrophil phagocytic index69.17 ± 3.70% with GHK + Dalargin and 72.17 ± 5.25% with GHK + Thymogen versus 31.67 ± 2.03% with fracture plus saline.Day 10 · Both p<0.05 versus fracture plus saline
Phagocytic index with GHK alone41.80 ± 2.50% with GHK, versus 31.67 ± 2.03% with fracture plus saline and 67.01 ± 4.33% without fracture.Table 1 marks p<0.05 versus both controls
Fracture radiographsThe authors describe a less visible fracture line in treated groups, particularly with combinations.Descriptive assessment
Day-10 neutrophil phagocytosis, Table 1
Day-10 neutrophil phagocytosis, Table 1
GroupPhagocytic index (%)Particles per phagocyteActivation index
Uninjured control67.01 ± 4.333.82 ± 0.192.51 ± 0.12
Fracture + saline31.67 ± 2.031.35 ± 0.050.43 ± 0.04
GHK41.80 ± 2.502.64 ± 0.141.19 ± 0.03
Dalargin43.50 ± 2.652.70 ± 0.151.17 ± 0.03
Thymogen55.00 ± 2.222.67 ± 0.171.41 ± 0.04
GHK + Dalargin69.17 ± 3.703.74 ± 0.252.35 ± 0.23
GHK + Thymogen72.17 ± 5.253.79 ± 0.172.71 ± 0.19
Thymogen + Dalargin60.00 ± 3.502.85 ± 0.191.71 ± 0.05

n=8 per group. Values are shown as M±m, as in the original. The group-specific significance flags are in the original table.

Source for these results ↗ · Reviewed 2026-11-16

Population / setting
Wistar rats (180–220 g) in a closed femoral fracture model. Table 1 lists eight groups with eight rats per group, including uninjured and fractured controls.
Source reviewed
Original proceedings paper, methods and Table 1.
Study limitations
  • The 2021 Mal conference paper repeats treatment-group phagocytosis means and errors exactly. The two reports are treated as overlapping evidence. The separate 2021 journal paper used intraosseous delivery and reports different numbers.
  • The paper describes radiographs qualitatively. The cellular assays do not establish fracture union, mechanical bone strength or clinical effects.

Reviewed 2026-11-16.

Read the source ↗

Animal research · 2021

GHK and Dalargin after rat fracture: neutrophil reserve in the 2021 conference report

GHK plus Dalargin raised the stimulated neutrophil NBT lab signal 2.9-fold and functional reserve 1.69-fold. GHK alone showed no substantial change on these oxygen-dependent measures.

Study notes and original source
2021Animal / experimentalRussian-language source

GHK and Dalargin after rat fracture: neutrophil reserve in the 2021 conference report

Unbound GHK, Dalargin and Thymogen given alone or in pairs. · Conference proceedings paper

G. S. Mal, A. M. Smakhtina, M. Yu. Smakhtin, A. A. Chulanova, K. I. Sunyaikin · Belikov Readings, 9th International Scientific and Practical Conference proceedings. Pyatigorsk, 2021; pp. 230–237.

GHK plus Dalargin raised the stimulated neutrophil NBT lab signal 2.9-fold and functional reserve 1.69-fold. GHK alone showed no substantial change on these oxygen-dependent measures.

Results and tables

Reported findings and study design

At day 10 the investigators assessed neutrophil oxidative activity using spontaneous and stimulated nitroblue tetrazolium (NBT) reduction. Functional reserve was the ratio of stimulated to spontaneous NBT. They also measured uptake of latex particles.

Population or model The 2021 methods report 60 Wistar rats overall, with no per-arm allocation table. The overlapping 2014 publication gives eight rats per phagocytosis group. The denominators cannot be reconciled from the reports.

Dose, route and schedule

Intraperitoneal treatment from the day of fracture for 10 days. Unbound GHK and Thymogen at 0.5 µg/kg each and Dalargin at 1.2 µg/kg, alone or in pairs. Fracture controls received an equivalent volume of saline.

Protocol source ↗ · Original proceedings paper, methods and Figures 1–2.

Results · Original proceedings paper, methods and Figures 1–2.
MeasureResultComparison, timing and statistics
Stimulated NBT response in blood neutrophils2.9× with GHK + Dalargin, 1.75× with GHK + Thymogen and 1.74× with Thymogen + Dalargin.Reported fold changes versus fracture control
Neutrophil functional reserve1.69× with GHK + Dalargin, 1.31× with GHK + Thymogen and 1.28× with Thymogen + Dalargin.Versus fracture control. GHK + Dalargin approached the uninjured reference. · Day 10
Oxygen-dependent measures with GHK aloneThe authors reported no substantial effect.Figure 1 and results text
Latex uptakeThe GHK + Dalargin and GHK + Thymogen phagocytic indices were 69.17 ± 3.70% and 72.17 ± 5.25%, matching the 2014 results.

Source for these results ↗ · Reviewed 2026-11-16

Population / setting
The 2021 methods report 60 Wistar rats overall, with no per-arm allocation table. The overlapping 2014 publication gives eight rats per phagocytosis group. The denominators cannot be reconciled from the reports.
Source reviewed
Original proceedings paper, methods and Figures 1–2.
Study limitations
  • The published phagocytosis values repeat the 2014 report. The 60 animals stated in the 2021 methods are treated as overlapping with the earlier report. The 2021 intraosseous journal paper is a separate source with different methods and results.
  • A normal-range laboratory result alone cannot establish equivalence to uninjured animals. These experiments do not establish a combined clinical effect or reduced infection rates.

Reviewed 2026-11-16.

Read the source ↗

Lab research · 1999

Activity profiles of dalargin and its analogues in μ-, δ- and κ-opioid receptor selective bioassays

Isolated-tissue assays showed that D-Ala configuration and other sequence modifications altered potency, peptidase resistance and receptor preference. The tested Dalargin profile favored μ activity; this does not settle receptor contributions in every tissue or disease model.

[L-Ala²] analogue · 19-fold less potent; δ/μ activity ratio 6.78; naloxone KB 7.9 nM

Study notes and original source
1999In vitroEnglish abstract

Activity profiles of dalargin and its analogues in μ-, δ- and κ-opioid receptor selective bioassays

N. Pencheva, J. Pospišek, L. Hauzerova, T. Barth, P. Milanov · British Journal of Pharmacology. 128(3):569–576

Isolated-tissue assays showed that D-Ala configuration and other sequence modifications altered potency, peptidase resistance and receptor preference. The tested Dalargin profile favored μ activity; this does not settle receptor contributions in every tissue or disease model.

Results and tables

Reported findings and study design

Isolated animal tissues comparing Dalargin analogues at opioid-receptor assay sites.

Population or model Isolated preparations from guinea pig, hamster, mouse, rat and rabbit

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
[L-Ala²] analogue19-fold less potent; δ/μ activity ratio 6.78; naloxone KB 7.9 nM
[Met⁵] analogueNaloxone KB 5.5 nM
DalarginethylamideNaloxone KB 5.0 nM
N-methyl-[L-Phe⁴]-dalarginamideδ/μ ratio 0.00053; naloxone KB 2.6 nM
[D-Phe⁴] amide analoguesInactive in the reported assays

Each potency/ratio belongs to a particular analogue; the KB figures concern naloxone antagonism, not a Dalargin human affinity or dose.

Source for these results ↗ · Reviewed 2026-10-29

Population / setting
Isolated preparations from guinea pig, hamster, mouse, rat and rabbit
Source reviewed
Selected source text and metadata checked; full risk-of-bias review pending.
Study limitations
  • Animal-tissue bioassays, not a human efficacy or safety trial.
  • Dalargin analogues are not interchangeable with the parent peptide.

Reviewed 2026-10-04.

Read the source ↗

Experiment described in a patent · 2008

Dalargin and electropuncture for acute hearing injury after mine blasts — RU2323019C1

The patent describes 123 patients with blast-related mixed hearing injury. Its tables report complete restoration in 22.3%, improvement in 34.7% and no effect in 43% following combined treatment. Tinnitus improvement is also reported.

Study notes and original source
2008Patent / reported experimentsFull text available

Dalargin and electropuncture for acute hearing injury after mine blasts — RU2323019C1

· Russian patent RU2323019C1

The patent describes 123 patients with blast-related mixed hearing injury. Its tables report complete restoration in 22.3%, improvement in 34.7% and no effect in 43% following combined treatment. Tinnitus improvement is also reported.

Results and tables

Reported patent results

Reported findings

Hearing improved in some patients, while 43% had no reported treatment effect.

Patent report of 123 patients with blast-associated mixed hearing loss receiving Dalargin plus electropuncture; historical/prototype methods are compared.

Population or model Patent report of 123 patients with blast-associated mixed hearing loss receiving Dalargin plus electropuncture; historical/prototype methods are compared.

Results · Description: 123-patient observations and Tables 2–3; tinnitus narrative.
MeasureResultComparison, timing and statistics
Hearing outcome22.3% complete restoration, 34.7% improvement, 43% unchangedReported proportions; no modern randomized comparison established · After the treatment course
Hearing thresholdsAverage reductions reported in the 15–30 dB rangeWithin-cohort change across speech/high frequencies · p<0.05 reported
Tinnitus49 patients reported complete disappearance; 9 less intensity; 5 unchanged63/123 had tinnitus initially; percentages in the source use the whole cohort denominator
Comparison with prior methodsComplete restoration 22.3% versus 7.3% and 9.8%; no effect 43% versus 67% and 64%Comparator cohort sizes and concurrent comparability are not established

Combined procedures, heterogeneous injuries, unclear comparator allocation and inconsistent percentage totals prevent a reliable Dalargin-alone effect estimate.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Patent report of 123 patients with blast-associated mixed hearing loss receiving Dalargin plus electropuncture; historical/prototype methods are compared.
Source reviewed
Selected source text and metadata checked; full risk-of-bias review pending.
Study limitations
  • Patent case material does not establish randomized allocation, blinding or Dalargin monotherapy efficacy.
  • One narrative passage reverses the restoration/improvement percentages; the summary follows the results tables.
  • Mixed middle- and inner-ear injuries and associated procedures limit attribution.

Reviewed 2026-11-06.

Read the source ↗

Animal research · 2000

Dalargin and liver function during acute hypoxia

The dissertation transcription reports longer survival in severe hypobaric hypoxia at testing times through 168 hours after ordinary intravenous administration and through 336 hours with erythrocyte-carrier delivery. Liver and oxidative-stress markers varied by delivery method and time.

Study notes and original source
2000Animal / experimentalRussian-language source

Dalargin and liver function during acute hypoxia

V. Yu. Kalinin · Candidate dissertation, 2000; web transcription

The dissertation transcription reports longer survival in severe hypobaric hypoxia at testing times through 168 hours after ordinary intravenous administration and through 336 hours with erythrocyte-carrier delivery. Liver and oxidative-stress markers varied by delivery method and time.

Population / setting
Rats; pressure-chamber model reported as approximately 12,200 m
Source reviewed
Selected source text and metadata checked; full risk-of-bias review pending.
Study limitations
  • Rat experiments do not establish human altitude protection or a seven-day clinical effect.
  • Original scan and survival tables remain to be reconciled; numerical survival values are withheld.
  • The early time point appears as 0.15 hours in the transcription; it is not safely interpretable as 15 minutes.

Reviewed 2026-10-04.

Read the source ↗

Animal research · 2011

Protective activity of Mildronate, Dalargin and Picamilon in experimental stress

The dissertation examines three separate pharmacological approaches to experimental stress, including behavior, gastric injury and nonspecific cellular immunity. The comparative program connects opioid-peptide research with Picamilon and Mildronate.

Study notes and original source
2011Animal / experimentalRussian-language source

Protective activity of Mildronate, Dalargin and Picamilon in experimental stress

T. I. Frantsuzova · Candidate dissertation, Saransk, 2011; 129 pages

The dissertation examines three separate pharmacological approaches to experimental stress, including behavior, gastric injury and nonspecific cellular immunity. The comparative program connects opioid-peptide research with Picamilon and Mildronate.

Population / setting
Experimental animal stress models
Source reviewed
Selected source text and metadata checked; full risk-of-bias review pending.
Study limitations
  • Selected transcription reviewed; full tables and statistical appraisal remain pending.
  • Head-to-head comparison is not evidence of a three-drug combination or human stress treatment.

Reviewed 2026-10-04.

Read the source ↗

Animal research · 1999

Post-resuscitation hemostasis correction with Dalargin and Mildronate

The Russian State Library verifies a 1999 experimental dissertation abstract on Dalargin and Mildronate in post-resuscitation hemostasis. A linked digital abstract is listed; efficacy and synergy claims require original-table review.

Study notes and original source
1999Animal / experimentalBibliographic record

Post-resuscitation hemostasis correction with Dalargin and Mildronate

F. I. Razgonov · Omsk, 1999; dissertation abstract, 25 pages

The Russian State Library verifies a 1999 experimental dissertation abstract on Dalargin and Mildronate in post-resuscitation hemostasis. A linked digital abstract is listed; efficacy and synergy claims require original-table review.

Population / setting
Experimental resuscitation research
Source reviewed
Selected source text and metadata checked; full risk-of-bias review pending.
Study limitations
  • Catalog metadata establishes the document, not the effectiveness of treatment.
  • Animal resuscitation experiments cannot be generalized to healthy-user combinations.

Reviewed 2026-10-04.

Read the source ↗

Comparison in people · 2023

Dalargin and oxidative stress in severe combined trauma: a prospective clinical study

Among 104 patients (38 Dalargin, 66 controls), the authors reported lower oxidative-stress markers and fewer ARDS/acute kidney injury events. Mortality and infectious complications were comparable; antioxidant activity remained below normal. Hospitalization was shorter among survivors receiving Dalargin.

Mortality · 8/38 (21.1%) versus 17/66 (25.8%) · p=0.6412; nonsignificant

Study notes and original source
2023Human comparative studyFull text available

Dalargin and oxidative stress in severe combined trauma: a prospective clinical study

V. V. Antonova, A. K. Evseev, I. V. Goroncharovskaya, A. Yu. Ryzhkov, O. A. Grebenchikov, A. K. Shabanov · Annals of Critical Care. 2023;(4):185–196

Among 104 patients (38 Dalargin, 66 controls), the authors reported lower oxidative-stress markers and fewer ARDS/acute kidney injury events. Mortality and infectious complications were comparable; antioxidant activity remained below normal. Hospitalization was shorter among survivors receiving Dalargin.

Results and tables

Reported findings and study design

Reported findings

ARDS and kidney injury were less frequent; mortality, infection and overall ICU stay did not differ significantly.

104 trauma patients: 38 Dalargin, 66 controls; allocation safeguards unverified.

Population or model 104 severe combined-trauma patients

Results · Original publisher HTML, selected results and Table 2
MeasureResultComparison, timing and statistics
Mortality8/38 (21.1%) versus 17/66 (25.8%)p=0.6412; nonsignificant
ARDS2/38 (5.3%) versus 14/66 (21.2%)p=0.0457
Acute kidney injury1/38 (2.6%) versus 13/66 (19.7%)p=0.0286
Overall ICU stay12.5 [6.0–34.5] versus 15.0 [5.0–34.0] daysMedian [IQR]; narrative prints 36.5 for the first upper quartile · p=0.8635; nonsignificant
ICU stay among survivors29.0 [12.0–36.0] versus 36.5 [21.8–54.0] daysSurvivor subset; selection may bias comparison · p=0.0015
Infection and antioxidant activityInfections comparable; antioxidant activity remained below normal

Dalargin versus standard care throughout. Unequal groups and unverified assignment prevent causal inference. No survival benefit established.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
104 severe combined-trauma patients
Source reviewed
Original publisher HTML, selected clinical outcomes and Table 2 checked. Overall and survivor-only ICU stay distinguished; narrative/table upper-quartile discrepancy retained.
Study limitations
  • Unequal groups; randomized allocation and blinding not established in this appraisal.
  • Biomarker changes do not prove improved survival; survivor-only length of stay requires caution.

Reviewed 2026-11-06.

Read the source ↗

Animal research · 2002

Receptor specificity of the antiarrhythmic effect of Dalargin and DADLE during myocardial reperfusion

The experimental report describes prevention of ventricular arrhythmias when Dalargin or DADLE was given before coronary reperfusion. It investigates opioid-receptor involvement rather than establishing a clinical antiarrhythmic treatment.

Study notes and original source
2002Animal / experimentalEnglish abstract

Receptor specificity of the antiarrhythmic effect of Dalargin and DADLE during myocardial reperfusion

· Indexed original publication; PMID 12124638

The experimental report describes prevention of ventricular arrhythmias when Dalargin or DADLE was given before coronary reperfusion. It investigates opioid-receptor involvement rather than establishing a clinical antiarrhythmic treatment.

Results and tables

Reported findings and study design

Coronary-reperfusion experiment: Dalargin or DADLE 0.1 mg/kg immediately before reperfusion.

Population or model Experimental myocardial reperfusion

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
Ventricular arrhythmiasPrevention reported
μ-receptor blockadeAbolished the antiarrhythmic effect

Numerical arrhythmia counts not supplied in the indexed abstract.

Source for these results ↗ · Reviewed 2026-10-29

Population / setting
Experimental myocardial reperfusion
Source reviewed
Selected source text and metadata checked; full risk-of-bias review pending.
Study limitations
  • Preclinical model; no human treatment benefit established.
  • DADLE and Dalargin are distinct peptides.

Reviewed 2026-10-04.

Read the source ↗

Explore related historical combinations ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗